DAX+0,15 % EUR/USD-0,09 % Gold+0,02 % Öl (Brent)-0,31 %

Viragen - aktueller Artikel im Science Magazin - 500 Beiträge pro Seite



Beitrag schreiben

Begriffe und/oder Benutzer

 

Heute steigt die Aktie nicht nur im außerbörslichen Handel, wie in den letzten Tagen üblich, sondern auch im regulären Handel Momentan bei 0,14 US$ (+27,3%). Vielleicht ist diese aktuelle Meldung der Grund:

Viragen Featured In `Science Magazine`

PLANTATION, Fla., May 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) today announced its Avian Transgenic Production Technology Project is featured in an article in the May 2, 2003 edition of "Science."

The article by Joe Alper entitled: "Hatching the Golden Egg: A New Way to Make Drugs" discusses Viragen`s project with Scotland`s Roslin Institute to create flocks of transgenic chickens as a cost-effective and efficient manufacturing platform for the large-scale production of protein-based drugs. The article can be accessed at Viragen`s website at http://www.viragen.com.

About Viragen, Inc.

Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include human natural alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen`s strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the entire biopharmaceutical industry.

Viragen is publicly traded on the American Stock Exchange (VRA). Viragen`s majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen`s key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America`s Blood Centers and the German Red Cross.

For more information, please visit our Web site at: www.Viragen.com

Viragen, Inc. Corporate Contacts:
Douglas Calder, Director of Communications (Media & Investor Contact)
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com


Gruß Fraktal
Mein Englisch ist leider nicht das beste...

Vielleicht kannst Du es ja mal sinngemäß übersetzen?!

;)
schnpchenjäger
habe text sinngemäss überstzt:

Viragen-
News in `Wissenschaftszeitschrift`

Plantage, Fla 6. Mai 2003 /PRNewswire-FirstCall über COMTEX/-viragen, Inc. (Amex: VRA) heute kündigte an, daß sein Avian Transgenic Produktionstechnologieprojekt in einem Artikel in der Mai2, 2003, Auflage der "Wissenschaft" erörtert worden ist.

Der betreffende Artikel von Joe Alper:

Das Goldene Ei:
Eine neue Art, Medikamente zu machen, "erörtert Viragens Projekt mit Schottlands Roslin Institut, um Herden von transgenen Küken als eine kostenwirksame und effiziente Herstellungsbühne für die Großproduktion von eiweißbasierten Medikamenten zu schaffen. Auf den Artikel kann an Viragens Web-Site an http://www.viragen.com zugegriffen werden.

Über Viragen ist Inc.

Viragen eine Biotechnikgesellschaft, die sich auf die Forschung, Entwicklung und Kommerzialisierung von Naturtalent und recombinant eiweißbasierte Medikamente spezialisiert, die dafür entworfen sind, einen breiten Bereich von Virus- und bösartigen Krankheiten zu behandeln. Diese eiweißbasierten Medikamente schließen menschliche natürliche Alphainterferon, monoclonal Antikörper, peptide Medikamente und therapeutische Impfstoffe ein. Viragens Strategie schließt auch die Entwicklung der Avian Transgenic Technologie für die groß angelegten, kostenwirksame sowohl die Herstellung seines Portefeuilles von eiweißbasierten Medikamenten als auch den Angebotsvertrag ein, der für die ganze biopharmaceutical Industrie herstellt.

Viragen wird öffentlich auf der amerikanischen Börse (VRA) gehandelt. Viragens Mehrheit besaß Tochtergesellschaft, Viragen international, Inc., wird öffentlich auf der nicht rezeptpflichtigen Anzeigetafel (VGNI) gehandelt. Viragens Schlüsselpartner und Lizenzgeber schließen ein: Roslin Institut, Gedenksloan-Kettering Krebszentrum, nationale Institute der Gesundheit, Krebsvereinigtes Forschungskönigreich, Universität von Nottingham (Vereinigtes Königreich), Universität von Miami, Amerikas Blutzentren und das deutsche rote Kreuz.

Zwecks weiterer Informationen bitte besuchen Sie unsere Web-Site an: www.Viragen.com

Viragen, Inc. korporative Kontakte:
Douglas Calder, Direktor des Fernmeldewesens (Medien- & Anlegerkontakt)
anrufen: (954) 233-8746; faxen: (954) 233-1414
Email: dcalder@viragen.com

einstieg zu ca. 0,10 war wohl das beste was man tun konnte-
denke dass hier riesenpotential vor uns liegt.

gruss
sukashi
sukashi
Der Kurs steigt heute in USA kräftig weiter, momentan auf 0,17 US$, während er in Deutschland bei knapp übr 0,14 € pendelt. Das ist ein satter Abschlag von 7% !!

Ich nehme mal an, dass die Mehrheit den Kursanstieg wieder für eine kurzfristige Angelegenheit hält und man sich nicht noch einmal abzocken lassen will, wie vor ein paar Tagen. Vielleicht nutzen auch viele von den kurzfristigen Zockern die Gelegenheit, schnell wieder auszusteigen, wenn auch mit Verlust.

Gruß Fraktal
Hier mal ein deutscher Artikel zu der Thematik. Ist zwar schon 2 Jahre alt, aber was sind 2 Jahre in der Gentechnik.


GEO Magazin 03/01 - Tiere als Therapeuten | Seite 1 von 1 |

Pharmaforschung: Das Huhn, das heilende Eier legt
"Pharming" heißt die moderne Tiernutzung in der Pharmaindustrie. Das neueste Wunschtier ist ein gentechnisch verändertes Huhn, dessen Eier medizinisch wirksame Substanzen enthalten


High-Tech-Firmen der Gen-Branche haben Verfahren entwickelt, das Genom von Haustieren zu verändern; zum Beispiel so, dass Ziegenmilch danach pharmazeutische Wirkstoffe enthält, die für Medikamente abgeschöpft werden können. In Deutschland ist es gelungen, den Blutgerinnungsfaktor VIII, dessen genetisch bedingtes Fehlen zur Bluterkrankheit führt, im Euter eines Schafes zu produzieren. Bislang wurde der Faktor aus menschlichem Spenderblut gewonnen.

Eier und Pillen in einem? Das gewöhnliche Haushuhn soll nach Wunsch von Gentechnikern zur Apotheke werden

Beim Pharming wird das für die Wirkstoffproduktion zuständige Gen mit einer hauchdünnen Nadel in den Kern einer befruchteten Eizelle eines Tieres injiziert und in ein Chromosom eingebaut. Diese so genannte transgene Eizelle wird dann in ein Muttertier reimplantiert, das zuvor durch Hormone empfangsbereit gemacht worden ist. Dessen Nachkommen tragen das eingeschleuste Gen in allen Körperzellen und bilden den Grundstock einer neuen Herde.

Dieses Verfahren, bislang erprobt an Säugetieren wie Kühen, Schafen, Ziegen oder Kaninchen, soll nun auch auf Hühner ausgeweitet werden, denn Eier gewährleisten eine schnellere und praktisch unbegrenzte Herstellung der gewünschten Substanzen.

Eine Henne ist imstande, im Jahr ungefähr 250 Eier zu legen, von denen jedes bis zu 0,5 Gramm des Wirkstoffes enthalten kann.

Vorreiter dieser Forschungen sind neben dem Roslin Institute in Edinburgh - bekannt im Zusammenhang mit dem geklonten Schaf "Dolly" - amerikanische Firmen wie Viragen und AviGenics. AviGenics experimentiert mit Hühnern, die so genannte Alpha-Interferone produzieren sollen: Eiweißstoffe, die bei chronischen Virusinfektionen und in der Krebstherapie eingesetzt werden.

Alle Produkte befinden sich aber noch in der Testphase. Und die Mikroinjektion lässt bislang noch an Effektivität zu wünschen übrig: Nur ein bis zwei Prozent der Gentransaktionen nach dieser Methode verlaufen erfolgreich. Außerdem ist das Verfahren nicht risikolos.

Zwar kann beim Gen-Pharming ausgeschlossen werden, dass die Produkte Hepatitis-Erreger enthalten; ob dies auch für BSE-Erreger gilt, ist aber noch nicht abzusehen. Auch reagieren viele Menschen allergisch auf Tierprodukte. Und schließlich: Ordnet sich zum Beispiel ein Gen an der falschen Stelle im Genom ein, können schädliche Erbkrankheiten auftreten.


Gruß Fraktal
Anbei der Artikel aus dem Science Magazin für interessierte Leser.

Der Artikel ist insgesamt äußerst positiv. Es wird dann schon deutlich, warum der Kurs angezogen hat und die Handelsvolumen so gross geworden sind (ich rede nur von den US Kursen und Umsätzen, nicht von den künstlich gepushten Vorgängen der Ahnunglosen hier in Deutschland). Außerdem wird klar, warum sich offensichtlich ohne grosse Probleme weitere Investoren finden, die Viragen Liquidität zur Verfügung stellen und dabei sogar Aktien zu einem deutlich über dem aktuellen Kurs liegenden Preis als Gegenleistung akzeptieren. Natürlich muß man auch berücksichtigen, dass insgesamt das Klima und die Bereitschaft für Risikokapital in USA besser ist als in Deutschland. Nach der Pleite mit dem Neuen Markt herrscht hier nur noch Katzenjammer und Panikmache, so dass neue Technoligien auf absehbare Zeit wieder nur in den USA eine Chance haben werden.

Hier mal als Zusammenfassung die Highlights aus dem Artikel:
- seit mehreren Jahrzehnten wird versucht, Gen manipulierte Hühner zu erzeugen, die in den Eiern menschliche Proteine produzieren
- viele Firmen haben ihre vergeblichen Bemühungen, das zu erreichen, eingestellt, ca. ein halbes Dutzend ist übriggeblieben, die weiterhin daran arbeiten
- nach vielen vergeblichen Versuchen ist jetzt nach 20 Jahren der Durchbruch gelungen: 3 verschiedenen Forscher Teams ist es gelungen, in sogenannten `proof-of-priciple` Experimenten nachzuweisen, dass sie genmanipulierte Hühner erzeugt haben, die gewisse Enzyme in ihren Eiern produzieren
- am weitesten sind die Firmen BioAgri und Viragen (zusammen mit dem Roslin Institute)
- Viragen arbeitet an der Genmanipulation der befruchteten Eier, BioAgri an Genmanipulation des Samens der Hähne, um Genveränderte Nachkommen zu erzeugen
- beide Firmen sind aufgrund ihrer Erfolge in Verhandlungen mit Pharmafirmen um Genmanipulierte Hühner zur Erzeugung von menschlichen Proteinen zu entwickeln. Man geht davon aus, dass es bald zu einem Abschluß kommen wird
- sollte man hierbei erfolgreich sein, könnten die Produktionskosten für menschliche Proteine, die zur Herstellung von Medikamenten z.B. gegen Krebs und Virusinfektionen, benötigt werden, um einen Faktor 100 reduziert werden. Für die Firma, die erfolgreich ist, werden die Hühnereier dann tatsächlich zu `goldenen Eiern`, da damit völlig neue Möglichkeiten in der Medikamentenherstellung zur Verfügung stünden.

Fazit des Artikels: Glücklicherweise haben einige Firmen bei der Entwicklung dieser Technologie durchgehalten. Die Früchte können jetzt geerntet werden. Man kann jetzt sehr optimistisch sein.


Falls Viragen auch noch die letzten Hürden nimmt, würde sich die Tür für ein Milliardengeschäft öffnen. Dagegen dürfte die in den letzten Tagen dikutierte Entwicklung eines Impfstoffes gegen SARS wirklich bestenfalls lächerlich sein. Auch der Aktienkurs von Viragen dürfte dann wohl in ganz anderen Regionen stehen.

Wer sich über BioAgri informieren möchte, hier ist der Link: http://www.bioagricorp.com/ Aus der Homepage kann man entnehmen, dass die in 2003 den Gang an die Börse planen.


www.sciencemag.org SCIENCE VOL 300 2 MAY 2003 729

Hatching the Golden Egg:
A New Way to Make Drugs

After 2 decades of work, researchers have succeeded in creating gene-altered chickens that can lay eggs containing human proteins

Chicken farms are among the most pungent places on Earth, but if a few hardy entrepreneurs have their way, it may soon be the sweet smell of success that wafts from buildings housing thousands of transgenic hens. As many as a half-dozen small companies are hoping to turn the common chicken into a pharmaceutical bioreactor, one that can meet the growing demand for protein-based human therapeutics.

The idea is deceptively simple: Insert human genes into chickens and get them to make human proteins in egg whites. "Transgenic chickens should be near-perfect bioreactors for making large amounts of pure recombinant proteins," says Ann Gibbins, an avian biologist at the University of Guelph in Ontario, who did the pioneering studies in the field and trained many of those scientists now achieving success. But, as she found out the hard way, putting the scheme into practice has been tough. Now, after 2 decades of struggles, researchers are reporting numerous successes in making transgenic chickens. The next-generation bioreactor should follow close behind.

As far as the drug industry is concerned, such transgenic chickens will most certainly be laying golden eggs. It`s just a matter of time, drug companies say, before they will be riding a wave of new health products based on manufactured human proteins. Already, they have concocted more than 300 human antibodies in the lab and begun testing them against a variety of human ailments - from cancer to viral infections to immune system disorders. But the companies need a better way to make these products. Current methods can be inefficient: The biotech firm Amgen, for example, has been having trouble meeting demand for its arthritis medication Enbrel, which contains a human protein made by Chinese hamster ovary cells.

The math of making drugs in chicken eggs is appealing. Each commercial hen lays about 250-plus eggs a year, at a nickel apiece. Each egg contains nearly 4 grams of egg white, comprising a mere eight proteins. Get a transgenic chicken to add 100 milligrams of a recombinant protein to that mix, Gibbins says, and the final cost for purified protein should be about $10 per gram, 100-fold less than the cost of current systems using cultured mammalian cells. Compared with other proposed animal production systems - cows or goats, for example - chicken flocks are easy to ramp up in months. There are other benefits as well: Commercial egg farms are already secure enough that a transgenic chicken, for instance, is unlikely to escape into the wild and breed. And there`s a bureaucratic comfort factor: The U.S. Department of Agriculture and the Food and Drug Administration are familiar with eggs as bioreactors because many vaccines, including those against influenza, are already produced in chicken eggs, although not transgenic ones.

Human biology also suggests why eggreactors should work better than alternatives such as bacteria or nonhuman mammalian cells. "Chickens add sugars to finished proteins in much the same way that humans do, something that can`t be said for most other protein production systems, current or envisioned," explains virologist Bill MacArthur, president of GeneWorks, a chicken research firm in Ann Arbor, Michigan. Proteins finished with the human glycosylation pattern are more active biologically.

But for all the potential benefits, "creating a transgenic chicken has proven to be a far greater challenge than we ever expected," says Gibbins. Although reports of success
have appeared in the literature every couple of years, none has panned out. Either the introduced genes failed to carry over into later generations or the chickens failed to produce the desired protein in their eggs. "It left us all thinking that it was going to take some kind of magic to ever make a transgenic chicken egg."

The magicians have arrived. At least three research teams using different methods have now shown that they can make transgenic chickens in proof-of-principle experiments. "Nobody has a transgenic chicken ready to produce a pharmaceutical today, but the field has now gotten to a place where this will happen," says developmental biologist Jim Petitte, whose group at North Carolina State University, Raleigh, developed a transgenic chicken that produces the bacterial enzyme ß-galactosidase in its eggs.

Needle in a haystack

Much of the trouble in creating a transgenic bird arises from some unusual features of avian reproductive biology: the sheer size of the egg and the difficulty of harvesting one before it has begun growing into a chick. The most common way to make a transgenic animal is to harvest a newly fertilized egg and inject foreign DNA directly into this single cell`s nucleus using a microscope and an ultrathin syringe needle. Eggs are easy to harvest when laid, but by that stage the zygote has already grown into a 60,000-cell mass. Harvesting the zygote from the chicken`s oviduct, difficult and expensive in itself, does yield a single cell, but one almost impossible to find within the viscous, yellow yolk.

Helen Sang, an avian molecular biologist at the Roslin Institute in Midlothian, U.K., is
one of the few researchers in the world to have figured out how to harvest a newly fertilized zygote and inject it with DNA or manipulate the 60,000-cell zygote of a freshly laid chicken egg and still get it to hatch into a transgenic chicken. Working with researchers from Viragen in Plantation, Florida, Sang has successfully created transgenic chickens that express a green fluorescent protein and are able to pass the introduced genes on to subsequent generations.

In this proof-of-principle study, Sang`s team used a lentivirus-based gene delivery system engineered at Oxford BioMedica in London to transfer the gene for green fluorescent protein or for ß-galactosidase into the DNA of chick embryos from freshly laid eggs. The injected embryos were then transferred to a host shell whose top had been carefully removed. Plastic wrap sealed the breech in the eggshell, allowing about 30% of the reconstructed eggs to develop and hatch normally. Of the eggs that hatched, 10 were transgenic roosters, evidence that the introduced gene had incorporated itself into the chicken`s DNA. Upon mating, each rooster successfully produced up to 29% transgenic offspring expressing the green fluorescent protein or ß-galactosidase, which Sang characterizes as "remarkably successful … far better than anything we`ve seen before." Using Oxford BioMedica`s lentivirus system, she is now developing a transgenic chicken designed to express a "clinically relevant human monoclonal antibody." By linking the gene for this antibody with the promoter for one of the egg-white proteins, Sang hopes to have it expressed in commercial quantities within the egg white.

Rather than try to manipulate a chicken egg, researchers at BioAgri in City of Industry, California, are working with rooster sperm. The key to this strategy is a monoclonal antibody, developed by BioAgri scientists, that binds specifically to the surface of sperm and allows DNA linked to the antibody to enter the sperm cell and incorporate itself into the sperm`s genome.

Using this sperm gene-transfer technique, developmental biologist Jin Qian and his colleagues have created two different transgenic chickens that produce human interferon a(alpha) and interferon ß(beta). The BioAgri researchers have shown that the interferon genes are stably transmitted across two generations of offspring so far. In addition, their subsequent study using green fluorescent protein linked to the lysozyme gene promoter demonstrated successful gene expression in egg white. The chicks from that experiment are nearing maturity and will be bred to see if this gene is passed to the offspring.

Based on their successes so far, both Viragen, which supports Sang`s work, and BioAgri are now negotiating with pharmaceutical companies to develop transgenic chickens that will make human proteins for clinical development. Petitte, who is not associated with either firm, wouldn`t be surprised if these deals were inked soon, a sign that this field is finally realizing its promise. "In the late `80s, lots of pharmaceutical and biotech companies had transgenic chicken programs because everyone saw the potential for lowering production costs, but they all got off the field when their programs went nowhere," says Petitte. "Fortunately, some of us were stubborn, and now the payoff is here. It`s time to be optimistic."

–JOE ALPER
Joe Alper is a writer in Louisville, Colorado.

Gruß Fraktal
Da Viragen ja nach der Kursexplosion in aller Munde ist, hole ich diesen Thread noch einmal hoch für alle, die vielleicht noch an diesen Infos interessiert sind.
Übrigens: Schlußkurs heute: 0,43 US$ (+260%)

Gruß Fraktal
Guten Morgen @all
wer denkt denn jetzt an einem Austieg ??
die 0,40 sollten Heute früh bei uns zu sehen sein
die vorböse sollte man auch nicht allzuviel beachtung
schenken wenn es nur zwei oder drei Cent hochgeht
erstmal bis 15:30 abwarten und um 16:00 reagieren
denn bis dahin kann viel passieren.
Der Kurs kann weiter steigen aber auch wieder fallen

mfg jojo
Viragen ist jetzt in eine interessante Lage gekommen.

Seit 2 Jahren geht der Kurs kontinuierlich abwärts, von ca 1,5 US$ bis auf 0,05 US$ im April 2003. Es wurde massiv Geld verbrannt, insgesamt ca 100 Millionen US$ und der Durchbruch in der Forschung kam nicht wie erwartet. Auch die Produktion von Multiferon läuft bisher nur mit Verlusten, der Umsatz war in 2002 ca 1,2 Millionen US$, der Verlust lag bei 11 Millionen US$. Die Cash Reserven waren bis auf 16 000 US$ verbraucht, so dass Viragen kurz vor der Pleite stand. Also insgesamt das übliche Szenario: der Kurs fällt, die schlechten Nachrichten folgen, Investoren ziehen sich zurück, der Kurs fällt weiter: ein Teufelskreis ! Die Wahrscheinlichkeit für eine Insolvenz lag bei über 90%, was sich ja auch im Kurs gezeigt hat.

Dann gelingt Viragen das fast Unmögliche: man findet einen Investor, der in letzter Minute noch einmal eine signifikante Größenordnung in Viragen steckt: zunächst 12 Mil. US$ (1.4.2003), dann noch einmal 2,3 Mil US$ (30.4.2003) gegen Ausgabe von Aktien zu 0,2 US$ (der Kurs stand mittlerweile bei ca 0,13 US$). Damit hat man den Kurs zum Anspringen gebracht, denn die Insolvenz ist zunächst abgewendet. Jetzt agiert man sehr geschickt: es kommen eine Reihe von positiven News (Artikel in Science Maganzine, SARS Patent, neue Lieferverträge für Mulitferon). Es geht Schlag auf Schlag. Die letzte Meldung von heute bedeutet praktisch eine Verdreifachung des jährlichen Umsatzes. Der Kurs zieht jedesmal deutlich an. Er fällt zwar auch wieder teilweise zurück, aber es ist gelungen, ihn im Bereich von 0,35 - 0,40 US$ zu halten. Die Umsatzvolumen sind gewaltig. Die Investoren, die gegen Aktien zu 0,20 US$ Kapital eingeschossen haben, sind schon dick im Plus. Damit könnte ein wichtiger psychologischer Effekt gelungen sein: Der Teufelskreis ist beendet und in das Gegenteil (ich nenne das mal Positivspirale) gedreht worden: der Kurs zieht an, es gibt positive news, weitere Investoren werden aufmerksam, der Kurs steigt weiter ! Aus meiner Sicht hat sich die Wahrschenlichkeit für ein Überleben jetzt auf 60% erhöht.

Wie könnte es jetzt weitergehen ?

In dem Science Artikel wird davon gesprochen, dass Viragen in Verhandlung ist über eine Kooperation mit einem grossen Pharmaunternehmen für die Weiterentwicklung der transgenen Hühner. Vielleicht war das Interesse der Pharmaunternehmen bisher nicht sonderlich groß. Das könnte sich jetzt durch den steigenden Kurs und die News geändert haben. Jetzt sieht man, dass ein Investment sich unter Umständen schnell bezahlt machen könnte. Zudem ist die Technologie der transgenen Hühner offensichtlich weit fortgeschritten. Gelingt der Durchbruch, ist jede Firma, die daran beteiligt ist, der grosse Held im Kampf gegen die Geißel der Menschheit im neuen Jahrtausend: Virenkrankheiten und Krebs. Klappt es nicht, ist es auch nicht schlimm, da es für eine grosse Firma ja nur um Beträge aus der Portokasse geht. Da kauft man eben eine Briefmarke weniger. Viragen schätzt ja den Kapitalbedarf noch auf weitere ca 20 - 25 Mil. US$ für die Zeit bis ein positiver Cash Flow aus eigener Kraft erwirtschaftet werden kann. Insofern könnte also ein erfolgreicher Abschluß solcher Verhandlungen als nächste positive News anstehen. Der Hammer wäre natürlich ein echter Durchbruch beim Huhn das goldene Eier legt ...

Was ist das Fazit ? Was sollte man als Aktionär jetzt machen ?

Ich bin auch unsicher. 40% Wahrscheichlichkeit für eine Insolvenz ist natürlich immer noch hoch. Geht der Fluß positiver news weiter, könnte der Kurs aber auch leicht schnell wieder die 1 US$ Marke überschreiten ! Also: Gier oder Gewinne mitnehmen. Letzlich muß das natürlich jeder selbst entscheiden. Aber die Story ist extrem spannend und es macht Spaß, dabei zu sein ....

Anbei noch mal eine Zusammenfassung der News seit Anfang April 2003:

IViragen Expands Drug Distribution Network
Agreement Valued at $9.5 Million
PLANTATION, Fla., May 27, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) and Viragen International, Inc. (OTC Bulletin Board: VGNI) today announced that they have entered into an exclusive distribution agreement with Arriani Pharmaceuticals S.A. to distribute Viragen`s natural human alpha interferon, Multiferon(TM), in Greece and designated Balkan countries. Subject to regulatory approvals, the agreement is estimated to be valued at $9.5 million based on sales revenue forecasts over the first five years.
The agreement provides that Arriani Pharmaceuticals, headquartered in Athens, Greece, shall take all measures necessary to achieve regulatory approvals for Multiferon in Greece, Cyprus and Slovenia following the Mutual Recognition Procedure (MRP) in the European Union, as well as to obtain and maintain the appropriate regulatory approvals in Bulgaria and Croatia. (MRP for Cyprus and Slovenia is subject to their pending acceptance into the EU.) Multiferon is expected to be available under a named patient sales program in Greece in the very near future. A "Named Patient" is a particular patient being treated by a doctor, for whom that doctor has issued a prescription for a drug not currently licensed.
"We are pleased to welcome another respected partner to our growing international natural interferon distribution network," stated Viragen`s Executive Vice President, Mr. Mel Rothberg. "The Greek and Balkan markets represent an attractive commercial opportunity to complement our expanding global marketing strategy."
Arriani Pharmaceutical`s Managing Director, CEO and Founder, Mr. Harry C. Lambridis, stated, "As one of the fastest growing pharmaceutical companies in Greece, we are pleased to add Multiferon to Arriani`s portfolio of innovative healthcare solutions. We will work closely with Viragen and look forward to offering Multiferon as an alternative to recombinant interferon for the treatment of a broad range of viral and malignant diseases such as hepatitis and certain cancers."

Viragen Signs Drug Distribution Agreement for Hong Kong
PLANTATION, Fla., May 22, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) and Viragen International, Inc. (OTC Bulletin Board: VGNI) today announced that the Companies have entered into an exclusive distribution agreement with CJ Pharma, U.S. Pharmaceutical Division of CJ Corporation, and the CJ Hong Kong Ltd. subsidiary, as exclusive distributors of natural interferon in Hong Kong. Viragen`s human leukocyte-derived alpha interferon is currently approved in Hong Kong as a second-line therapy for the treatment of patients with Hairy Cell Leukemia (HCL) or Chronic Myelogenous Leukemia (CML) who did not respond to recombinant (synthetic) interferon regimens.
CJ Corporation (formerly Cheil Jedang) was established as the first manufacturing operation unit of the Samsung Group in 1953. Now a split-off of Samsung Group, the CJ Group recorded over $6 billion in revenues last year, conducting business with over 60 different countries through its thirty-two offices around the world.
"We are very pleased to build upon our relationship with a proven leader such as CJ Pharma," stated Viragen`s Executive Vice President, Mel Rothberg. "We have been working very closely with CJ to commercialize our natural interferon in previously assigned territories in Latin America. Now we are expanding our work together to include the introduction of the drug into the Hong Kong market."
CJ Pharma exclusively represents Viragen`s products in the following territories: Brazil, Chile, Uruguay, Peru, Costa Rica, Honduras, Nicaragua, Guatemala, Panama and Hong Kong. CJ Pharma is responsible for all costs associated with the regulatory approval process, including clinical trials if required, in each of the respective countries.
CJ Hong Kong`s General Manager, Mr. Jong Hwan Park, stated, "We are excited to attain the rights to distribute such a potent anti-viral product with Viragen`s multi-subtype human interferon. Our immediate priority is to expand the indications for which the product is currently approved to include a broad range of viral and malignant diseases and we are proceeding with the regulatory registration process."
Dr. Andrew Gorman, Vice President, CJ Pharma (Princeton, NJ), stated, "We believe that natural interferon represents a very attractive international market opportunity for us and our commitment to Viragen now extends from South America to Asia. Our foremost priority is to offer products that promote better health for everyone and this immune-enhancing drug offers that kind of promise in treating a variety of diseases."

Viragen Files Patent Application For Drug To Target SARS
PLANTATION, Fla., May 20, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) today announced that it has filed a patent application covering the use of natural human leukocyte-derived alpha interferon for the treatment and prevention of severe acute respiratory syndrome (SARS).
"Previous reports have identified alpha interferon as a prime candidate for the treatment of SARS," stated Viragen`s Director of Research (Emeritus), Professor William H. Stimson. "Groundbreaking research has determined that the main causing agent of SARS belongs to the coronavirus family. Previous studies in experimental coronavirus infections have found that a relatively high dosage of alpha interferon (9 MIU/day), begun shortly before virus challenge, provided protection against both infection and illness.(1) We believe natural, leukocyte-derived interferon is worthy of consideration in the experimental treatment of SARS and we are supporting appropriate research in this important area by providing samples of our product to international research organizations for evaluation."

VIRAGEN FEATURED IN SCIENCE MAGAZINE
PLANTATION, FLORIDA – May 6, 2003 – Viragen, Inc. (AMEX: "VRA") today announced its Avian Transgenic Production Technology Project is featured in an article in the May 2, 2003 edition of Science.
The article by Joe Alper entitled: "Hatching the Golden Egg: A New Way to Make Drugs" discusses Viragen`s project with Scotland`s Roslin Institute to create flocks of transgenic chickens as a cost-effective and efficient manufacturing platform for the large-scale production of protein-based drugs. The article can be accessed at Viragen`s website at http://www.viragen.com.


Viragen Obtains Debt Financing
PLANTATION, Fla., Apr 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) today announced that it has raised $2.27 million in debt financing from a group of its current institutional stockholders and intends to use the proceeds to progress with its business plan to commercialize its portfolio of healthcare technologies including Multiferon(TM), Avian Transgenic Production Technology and Oncology Projects.
Viragen raised $2.27 million in gross proceeds from the sale of secured convertible debentures in a private placement with a group of its existing institutional stockholders. The debentures, issued under an original issue discount, bear interest at the rate of 10% per annum, are payable over 24 months and have a maturity date of August 1, 2005. The debentures are convertible into shares of Viragen common stock at the option of the Company at a fixed price of $0.20 per share if the market price exceeds $0.25 per share. The debentures may be converted at any time, in whole or in part, at the option of the investors at $0.20 per share. The conversion price, which represents a premium to the average price of Viragen`s common stock over a several day period prior to the closing, is not subject to any price resets. The complete terms of the financing will be detailed in a registration statement to be filed with the Securities and Exchange Commission.
Viragen`s Chairman, Mr. Carl Singer, stated, "This debt funding provides us with immediate working capital that we believe will be sufficient to fund our operations until we are able to access our equity line of credit following stockholder approval. With secured funding in place, the entire Viragen team remains committed to achieving our scientific and commercial goals as we deliver innovative healthcare technologies and strive to build stockholder value for our investors." Earlier this month, Viragen announced an agreement to access a $12 million equity line of credit.
"We remain very excited about the promise of Viragen`s drugs and technologies," stated investor spokesperson, Mr. Andrew Reckles, General Partner of Palisades Master Fund LP. "With new opportunities opening up for the use of Multiferon and with the prospect of Avian Transgenic Technology fulfilling even just a fraction of its market potential, we believe that our investment in this company is attractively priced, even at a premium to the current market price."

Viragen Announces $12 Million Financing Agreement

PLANTATION, FLORIDA –
April 1, 2003 – Viragen, Inc. (AMEX: "VRA") today announced a two-year funding agreement that can provide up to $12 million in working capital from its largest institutional investor. Terms of the deal, structured in the form of an equity line of credit, will be detailed in a registration statement to be filed with the Securities and Exchange Commission (SEC).

Viragen`s management team recently announced a major restructuring plan designed to significantly decrease expenses, strengthen management, streamline operations and attract additional investments. As part of this plan, Viragen has obtained a $12 million equity line of credit from Palisades Master Fund LP, an institutional investment fund based in the British Virgin Islands. Palisades will provide capital in such amounts and at such times as Viragen may require and at Viragen`s sole discretion. Securities associated with such transactions may not be sold prior to the time the registration statement is declared effective by the SEC.

"We believe this funding commitment will provide the capital necessary for us to continue to demonstrate key commercial and scientific milestones," stated Viragen`s President and CEO, Mr. Robert Salisbury. "This agreement provides us with a viable financing option while we continue to seek additional investors and partnering opportunities."

"We are very strong supporters and believers in the Viragen story and their management team. With volatile world markets, war, and overall economic uncertainty, great small companies, especially in the biotechnology arena, have seen their stock price dramatically suffer," stated Mr. Andrew Reckles, Chairman of HPC Capital Management and General Partner of Palisades. "In evaluating such market opportunities, we have spent the last seven months getting to fully understand the enormous potential of Viragen`s products including Avian Transgenic Technology, which may revolutionize the way life-saving drugs are manufactured, and Multiferon™, which is generating sales as a safe and effective natural interferon for the treatment of many diseases. The new initiatives that management is taking to significantly reduce its cash burn rate have convinced us to commit, irrevocably, to fund the company, while we assist the company to find additional strategic and long-term financing commitments." HPC Capital is based in Atlanta, Georgia.

Gruß Fraktal
@Frakt
bin auch deiner Meinung, hab mich leider auch Kopflos zum Kauf zu 0,35 Euro verleiten lassen. Nachdem nun ein paar Tage vorbei sind, und der Kurs sich fast stabilisiert denke ich dass sich in den nächsten 4 Wochen die Richtung zeigt. An eine kurzfristige pleite denke ich nicht weil: im Moment geht geld wieder in Bios und die Chinesen stecken kein Geld in eine Pleite Firma.
Chartmike
ganz still und leise gehts nach oben...

Und keiner merkts :) So solls sein :)
@Hyper03

hab ich noch keine gefunden. Könnte mir aber vorstellen, dass da wieder einige mehr wissen als alle anderen.
Corporate Overview Corporate Overview Management & Directors Management & Directors Locations Locations Careers Careers Multiferon Multiferon Anti-cancer Projects Anti-cancer Projects Avian Transgenic Technology Avian Transgenic Technology Press Releases Press Releases Media Highlights Media Highlights Webcasts Webcasts Investor Highlights Investor Highlights FAQ FAQ Recent Filings Recent Filings SEC Filings SEC Filings VRA Stock Quote VRA Stock Quote VGNI Stock Quote VGNI Stock Quote Investor Contact Investor Contact


Pressekommuniqué FÜR SOFORTIG FREIGABE BEZIEHUNG ZWISCHEN DEN INVESTORENCKontakt:

Kommunikationen
Korporativ

Douglas Calder,
Direktor von Kommunikationen
Mel Rothberg
ExecutivcVizepräsident

(954) 233-8746 - Telefax (954) 233-1414
(954) 233-8746 - Telefax (954) 233-8743

E-mail: dcalder@viragen.com
E-mail: mrothberg@viragen.com


--------------------------------------------------------------------------------

VIRAGEN ERWEITERT DROGECVerteilungsnetz
- Vereinbarung bewertet bei $9,5 Million

PLANTAGE, FLORIDA? Mai 27, 2003? Viragen, Inc. (Amex: und Viragen International, Inc. (OTC BB: heute verkündet, daß sie einen exklusiven Verteilungsvertrag mit pharmazeutisch Produkten S.A. Arriani, Alphainterferon Viragen?s zu verteilen natürliches menschliches schlossen haben, Multiferon? , in Griechenland und in gekennzeichneten Balkan Ländern. Abhängig von Genehmigungen durch die zuständige Aufsichtsbehörde wird die Vereinbarung, bei $9,5 Million bewertet zu werden basiert worden auf Umsatzerlös-Prognosenover die ersten fünf Jahre geschätzt.

Die Vereinbarung setzt daß die pharmazeutischen Produkte Arriani voraus, Hauptsitz gehabt in Athen , Griechenland, ergreift alle Maßnahmen, die notwendig sind, Genehmigungen durch die zuständige Aufsichtsbehörde für Multiferon in Griechenland, in Zypern und in Slowenien nach dem Verfahren der gegenseitigen, in Anerkennung (MRP) im europäischen Anschluß zu erzielen, sowie, zu erreichen und beizubehalten die passenden Genehmigungen durch die zuständige Aufsichtsbehörde Bulgarien und Croatia. (MRP für Zypern und Slowenien ist abhängig von ihrer schwebenden Annahme in das EU.), Multiferon wird erwartet, um unter einem genannten geduldigen Verkaufsprogramm in Griechenland in nächster Zukunft vorhanden zu sein. A "genannter Patient" ist ein bestimmter Patient, der von einem Doktor behandelt wird, für den dieser Doktor eine Verordnung für eine Droge nicht z.Z. genehmigt herausgegeben hat.

?We freuen sich, einen anderen respektierten Partner zu unserem wachsenden internationalen natürlichen Interferonverteilungsnetz zu begrüßen? angegebener Executivvizepräsident Viragen?s, Herr Mel Rothberg. griechische und Balkan Märkte des?The stellen eine attraktive kommerzielle Gelegenheit dar, unsere erweiternde globale Marketing-Strategie ergäzunzen?

Geschäftsführender Geschäftsführer Arriani Pharmaceutical?s, CEO und Gründer, Herr Harry C. Lambridis, angegeben?As eins der schnellsten wachsenden pharmazeutischen Firmen in Griechenland, freuen uns wir, Multiferon Mappe Arriani?s der erfinderischen healthcarelösungen hinzuzufügen. Wir arbeiten nah mit Viragen und freuen, Multiferon als Alternative recombinant Interferon anzubieten nach der Behandlung einer ausgedehnten Strecke der Viren- und bösartigen Krankheiten wie Hepatitis und bestimmte Krebse?

Multiferon? ? Die Natürliche Wahl:

Multiferon ist in hohem Grade gereinigt, ein Multiformationsglied, das natürliche menschliche Alphainterferon, das von den menschlichen weißen Blutzellen abgeleitet wird und wird in Schweden für die Zweitlinienbehandlung von irgendwelchen genehmigt und alle Krankheiten, in denen recombinant (synthetische) Interferontherapie ausfiel, oder der Patient nicht imstande war, die Regierung zuzulassen, vermutlich wegen der Anordnung der neutralisierenden Antikörper.

Natürliches Interferon Viragen?s wird auch für Verkauf in den folgenden Ländern als Zweitlinientherapie für die Behandlung der haarigen Zellenleukämie (HCL) und der chronischen Leukämie Myelogenous (CML) genehmigt: Tschechische Republik, Ägypten, Hong Kong, Indonesien, Mexiko, Myanmar, Südafrika und Thailand. Arbeit ist fortwährend, die anerkannten Anzeigen in diesen Ländern zu erweitern.

Genehmigungs durch die zuständige Aufsichtsbehördeprozesse sind auch unterwegs in einer Anzahl von anderem südamerikanischem, Gegenden des mittleren Ostens und Fernen Ostens.

Vor-Lizenz und genannte Programme Patient Sales:

An in einigen Fällen ist es möglich für Multiferon, in einem Land vor der Gewinnung von Genehmigung durch die zuständige Aufsichtsbehörde verkauft zu werden, indem man zum Teilnehmen eine Vorlizenz oder genanntes geduldiges Verkaufsprogramm qualifiziert. Multiferon wird unter solchen Programmen zu bestimmten Ländern versendet, die solche Tätigkeiten zulassen. Diese Programme erlauben Ärzten, Multiferon zu den spezifischen Patienten auf einer begrenzten Grundlage vorzuschreiben, bis eine formale Drogezustimmung empfangen ist. Vorteilhafte Resultate von diesen Programmen sollten Wertsache beim Fortfahren prüfen, Multiferon als Alternative zu den recombinant Interferonregierungen in Position zu bringen und Mappe Viragen?s der klinischen Erfahrung zu erhöhen.

Der InterferoncMarkt:

Die Mehrheit einem Alphainterferon, das vermarktet werden, sind recombinant Interferon des Einzelnformationsgliedes. Therapiewiderstand ist nicht mit recombinant Interferon mit einem bedeutenden Prozentsatz der Patienten ungewöhnlich, die auf Standardtherapie reagieren nicht können. In einigen Fällen wird recombinant Interferon durch das immune System der patient?s zurückgewiesen, normalerweise verursacht durch die Anordnung der neutralisierenden Antikörper, die zu einen Verlust der klinischen Wirksamkeit führen können. Auch viele Patienten können nicht die nachteiligen Nebenwirkungen zulassen, die manchmal mit recombinant Therapie dazugehörig sind. Hohe Dosen von recombinant Interferon können die ernsten, sogar lebensbedrohenden Nebenwirkungen verursachen. Viragen hat beobachtet, daß in vielen Fällen, besonders wenn höhere Dosierungen angefordert werden, sein natürliches Interferon scheint, erhebliche Vorteile recombinant Interferonregierungen anzubieten. Der jährliche globale Interferonmarkt wird geschätzt, um $3 Milliarde zu übersteigen.

Mrp:

Eine pharmazeutische Firma, die im EU hergestellt wird, das bereits eine Marketing-Ermächtigung in einem EU-Mitgliedsstaat erreicht hat, kann auf einen oder mehr zutreffen andere Mitgliedsstaaten zum Erkennen er, in Übereinstimmung mit der Grundregel der gegenseitigen Anerkennung.

Über Viragen Inc..

Viragen ist eine Biotechnologiefirma, die auf die Forschung, die Entwicklung und die Kommerzialisierung der natürlichen und recombinant proteinbasierten Drogen sich spezialisiert, die entworfen werden, um eine ausgedehnte Strecke der Viren- und bösartigen Krankheiten zu behandeln. Diese proteinbasierten Drogen schließen natürliches menschliches Alphainterferon, monoclonal Antikörper, Peptiddrogen und therapeutische Impfstoffe mit ein. Strategie Viragen?s umfaßt auch die Entwicklung der VogelTechnologie Transgenic für die großräumige, kosteneffektive Herstellung seiner Mappe der proteinbasierten Drogen, sowie anbietenvertragsherstellung für die gesamte biopharmaceutical Industrie.



Viragen wird öffentlich auf der amerikanischen Börse (VRA) gehandelt. Besessene Tochtergesellschaft Viragen?s Majorität, Viragen International, Inc., wird öffentlich auf dem im Freiverkehr gehandelten Anschlagbrett (VGNI) gehandelt. Schlüsselpartner und Lizenzgeber Viragen?s umfassen: Institut Roslin, ErinnerungsKrebsmitte Sloan-Kettering, nationale Institute der Gesundheit, Krebsforschung Großbritannien, Universität von Nottingham (Großbritannien), Universität von Miami, Blutmitten America?s und das deutsche rote Kreuz.

Korporative Kontakte Viragen, Inc.

Douglas Calder, Direktor von Kommunikationen (Mittel u. Investorkontakt)
Telefon: (954) 233-8746; Telefax: (954) 233-1414
E-mail: dcalder@viragen.com


--------------------------------------------------------------------------------

Das vorangehende Pressekommuniqué enthält das Vorwärts-Schauen der Aussagen, die durch solche Terminologie wie?expects gekennzeichnet werden können?, oder ähnliche Ausdrücke. Solche Vorwärts-schauende Aussagen beziehen die bekannten und unbekannten Gefahren, die Ungewißheiten und andere Faktoren mit ein, die die tatsächlichen Resultate veranlassen können, zu allen zukünftigen Resultaten, Leistung oder Ausführungen materiell unterschiedlich zu sein, die durch solche Aussagen ausgedrückt werden oder angedeutet sind. Insbesondere konnten die management?serwartungen betreffend sind zukünftige Forschung, Entwicklung und/oder kommerzielle Resultate, Ungewißheiten in bezug auf klinische Versuche vorbei, unter anderem beeinflußt werden und Produktentwicklung; Verwendbarkeit der zukünftigen Finanzierung; unerwartetes regelndes verzögert oder Regierungsregelung im Allgemeinen; die Fähigkeit Company?s, Patent und anderen eigenen Schutz des geistigen Eigentums zu erreichen oder beizubehalten; und Konkurrenz im allgemeinen. Vorwärts-schauend sprechen Aussagen nur hinsichtlich des Datums, das sie gebildet werden. Die Firma beabsichtigt nicht, das Vorwärts-Schauen von Aussagen zu aktualisieren, um Umstände zu reflektieren, oder Fälle, die nach dem Datum die Vorwärts-schauenden Aussagen auftreten, werden gebildet.


--------------------------------------------------------------------------------

Klicken Sie HIER für vorhergehendes Pressekommuniqué.


Copyright© 2003 Viragen, Inc.. - VERZICHT
Es war ja lange ruhig um Viragen, jetzt hat sich der Chairmen gemeldet und sagt was zu den Stand der Zielsetzung für das 1. Halbjahr 2003 sowie die Ziele für die nächsten 12 Monate:

Viragen`s Chairman Presents Mid-Year Progress Report

PLANTATION, Fla., Jun 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- The following is a letter from the Chairman of Viragen, Inc. (Amex: VRA) and Viragen International, Inc. (OTC Bulletin Board: VGNI), Mr. Carl N. Singer. In addition to these comments, stockholders are referred to the Company`s Form 10-K and Form 10-Q (Annual and Quarterly Reports filed with the SEC); press releases and other publicly disseminated information; information posted on Viragen`s Website at www.Viragen.com; and other printed information which may be supplied by the Company on request.

Dear Stockholder,

On January 30th of this year, Robert Salisbury and I accepted the respective responsibilities of President & CEO and Chairman in steering Viragen through its next stage of progress, development and growth. In doing so, we have prioritized the initiatives of our Company to focus on those activities that we believe will result in Viragen reaching an appropriate market valuation for its valued stockholders. Over the past months, we have challenged our Board, Senior Management, employees and collaborative partners with achieving the following ambitious goals aimed towards building stockholder value:

2003 Goals - First Half Report

* Build Multiferon(TM) revenue
* Expand Multiferon(TM) indications and geographic approvals
* Enter into additional international supply and distribution agreements
* Report significant Avian Transgenics milestones
* Obtain debt financing by offering debentures convertible at a premium to market price
* Contain costs, cut cash burn rate, focus resources on priority programs
* Implement Director/Management stock-based compensation program

While it has been less than six months since setting these goals, I am pleased to report that tangible progress has been reported regarding all of these initiatives. We invite you to review these press announcements at www.Viragen.com. Our reported results demonstrate that our global Multiferon program is growing steadily and our R&D projects, including Avian Transgenic Technology and certain anti-cancer efforts, appear capable of fulfilling their promise. While our progress to date is encouraging, it is only the very beginning of our long-term strategy and vision. Over the next twelve months, we expect to continue to report important commercial and scientific milestones, which build upon all of the previously mentioned goals, as well as include the following:

2003/2004 Goals - Next 12 Months

* Strengthen our Board of Directors
* Obtain long-term beneficial financing
* Report combined production of Multiferon(TM) from two facilities in Sweden
* Secure early access Avian Technology production collaboration
* Enter into strategic partnerships (all platforms)
* Publish peer-reviewed data in medical publications
* Strengthen intellectual property (patent) portfolio
* Obtain independent research coverage
* Increase exposure to institutional and retail investors

On Wednesday, June 25th, we will hold a Special Meeting of Stockholders for the purpose of seeking stockholder approval regarding certain items including increasing the number of Viragen`s authorized shares. Our Board has determined that the approval of these measures would provide Viragen the flexibility to execute its long-range business plan. With the approval of these measures, we will have access to our recently announced $12 million equity line of credit, subject to SEC clearance.

We are concerned about potential dilution, so we intend to draw upon the equity line only as needed to fund our operations and progress our commercial and scientific programs. We have based our request for the increased authorization on a set of assumptions which provides for unexpected events and/or opportunities, but our intent is to minimize the use of authorized but unissued shares.

While the equity line should be capable of providing needed funding, we will continue to seek strategic partners and new investors which could reduce the number of equity transactions needed to fund operations. Growth and expansion of our commercial activities could also diminish our reliance upon equity transactions to fund our business plan. In addition, management continues to aggressively contain costs, direct resources to priority programs and work towards building stockholder value. We appreciate our stockholders` continued support.

Sincerely,

Carl N. Singer
Chairman of the Board

Gruß Fraktal
hab ich auch schon gesehen, und sofort gekauft, 14.000 st.
bin schon länger hinter viragen her.
andauernt kommen geile nachrichten rein wie:
patent für sars-mittel
markteintritt mexico krebsmittel / lungenentz......
gute fortschritte mit multiferon

ich sagte schon, die aktie ist innerhalb weniger wochen jenseits der 1EUR marke.
der akt. kurs ist überhaupt nicht fair !

sag nur gewinne von evotec mitnehmen, und rein in viragen.
nein stimmt der Kurs ist wirklich nicht fair,aber erklären wir das denen dadrüben mal ich weiss auch nicht was die dort wieder veranstalten,ich werde auch wieder nachkaufen und hoffe auf gute kurse:) so long
ich kann mir schon denken warum sie den kurs im amex niedrig halten. am 25.06. ist diese sped. versammlung, dort will man aktien veräussern zum jetzigen preis, warscheinlich hängt das damit zusammen, sicher bin ich mir nicht.
grad wieder eine empfehlung `STRONG BUY` von EquityOutlook.com.

habe zwar schon 14.000 Stück, würd gern nachkaufen, mein gehalt hab ich erst am 28.06. ! SCHEISSE !! werd wohl am Montag um Vorschuß bitten müssen
:laugh: :laugh:
Es geht heute wirklich unter sehr hohem Volumen wieder etwas deutlicher nach oben. Momentan sind knapp 25 Millionen Aktien über den (AMEX) Tisch gegangen und wir liegen bei 0,28 US$ (+17%) (auf Island aktuell sogar schon 0,29 US$). Anbei mal ein Chart den den Verlauf des letzten Jahres zeigt und vor allem den gigantischen Volumenanstieg vor 10 Wochen. Beim Kursabfall der letzten 4 Wochen hatten wir deutlich niedrigere Volumen als jetzt beim Anstieg. Ein gutes Zeichen.



Gruß Fraktal
über 45mio aktien gehandelt im amex ! USD 0,30
wer sagts denn ! heute gehts wieder nach oben.
freu mich drauf wenn die glocken wieder in den USA leuten.
will heute die 0,60 USD sehen.
ja wäre schön versuche gerade noch welche mit Limit zu 0,27 zu ordern verstehe aber langsam nicht wieso ich in Frankfurt mitlerweile schon 90 Minuten auf ausführung warte
Viragen Strengthens Board

New Director Adds Pharmaceutical, Wall Street and Legal Experience

PLANTATION, Fla., Jun 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) today announced the appointment of Mr. C. Richard Stafford to its Board of Directors. Mr. Stafford brings over 40 years of management experience from the legal, pharmaceutical and investment banking industries.

Mr. Stafford was a Vice President in charge of mergers and acquisitions for Carter-Wallace, Inc., a former New York Stock Exchange-listed international pharmaceutical, diagnostics and toiletries company. Carter- Wallace paid dividends for over one hundred years until its acquisition in 2001 for more than $1.1 billion. He was involved in the restructuring and sale of the company, which included the separation of the consumer products from the pharmaceutical businesses.

Prior to joining Carter-Wallace, Mr. Stafford was President of Caithness Corporation, an oil, gas and mineral exploration firm. At this time, he also taught evening classes at New York Law School. He has also served as a Vice President of Corporate Finance at the global investment banker, Bear Stearns, as well as the Director of Corporate Development of the Bristol-Myers Company and as an Associate at Milbank, Tweed, Hadley & McCloy. He is a cum laude graduate of Harvard College and a graduate of Harvard Law School.

"Richard Stafford is an outstanding addition to Viragen`s Board of Directors, bringing vast experience from helping lead world-class organizations in industries directly related to our business," stated Viragen`s Chairman, Mr. Carl Singer. "We look forward to working with him as we continue to implement commercial and scientific strategies designed to build stockholder value."

Mr. Stafford stated, "As an emerging biotech company that is initiating its drug sales program and has a portfolio of technology that is progressing promisingly, Viragen represents a particularly exciting opportunity. I look forward to working closely with the Board in helping guide this company to evolve as one of the elite in this challenging industry."

It was also announced today that Dr. Douglas Lind has volunteered to redefine his duties as part of Viragen`s ongoing restructuring program to contain costs. The Board was pleased to accept his offer to now serve as a consultant, advising in matters for corporate strategy. Dr. Lind remains committed to working with Viragen`s Board and Senior Management on matters related to financing, business development and other strategic activities. He remains a member of the Board and adds valuable experience from his former role as Senior Biotechnology Analyst from leading Wall Street firms Morgan Stanley and PaineWebber.

In other Board related news, it was announced that Mr. Bryan King has resigned from the Company`s Board of Directors.

Gruß Fraktal
Hier einige Infos zu der Aktionärsversammlung vom 25.6.2003. Die Anträge von Viragen wurden alle genehmigt:

ANNOUNCEMENT - Notice of Special Meeting of Stockholders
INVESTOR RELATIONS CONTACT:
Communications
Douglas Calder, Director of Communications
(954) 233-8746 - Fax (954) 233-1414
E-mail: dcalder@viragen.com

Viragen held a special meeting of stockholders at the Renaissance Plantation Hotel located at 1230 Pine Island Road, Plantation, Florida, on Wednesday, June 25, 2003 at 2:00 p.m. (EDT) As noted in the proxy, stockholders of record at the close of business May 27, 2003 were entitled to vote to authorize certain equity financings as well as to approve a proposal to increase the number of authorized shares from 250 million to 700 million.
The following items were approved by stockholders:
Report of Elections
1. Increase the Number of Authorized Shares - Stockholders approved of increasing the number of authorized shares of common stock from 250 million to 700 million.
2. Financing Transaction - Stockholders approved the possible issuance of more than 19.9% of Viragen common stock in a financing transaction pursuant to which Viragen received gross proceeds of $2,476,050 through the sale if its convertible debentures, common stock and common stock purchase warrants to 5 institutional investors.
3. Financing Transaction - Stockholders approved the possible issuance of more than 19.9% of Viragen common stock in a financing transaction pursuant to which Viragen received gross proceeds of $3,758,132 through the sale if its convertible debentures and common stock purchase warrants to 4 institutional investors.
4. Financing Transaction - Stockholders approved the possible issuance of more than 19.9% of Viragen common stock in a financing transaction pursuant to which Viragen has the right to require an investor to purchase up to $12,000,000 in shares of Viragen common stock.
Chairman`s Comments
Chairman Carl N. Singer stated, "Our Board has determined that the approval of these measures provides Viragen the flexibility to execute its long-range business plan. With the approval of these measures, we expect to have access to our recently announced $12 million equity line of credit, subject to SEC clearance."
"We are concerned about potential dilution, so we intend to draw upon the equity line only as needed to fund our operations and progress our commercial and scientific programs. We have based our request for the increased authorization on a set of assumptions which provides for unexpected events and/or opportunities, but our intent is to minimize the use of authorized but unissued shares."
"While the equity line should be capable of providing needed funding, we will continue to seek strategic partners and new investors which could reduce the number of equity transactions needed to fund operations. Growth and expansion of our commercial activities could also diminish our reliance upon equity transactions to fund our business plan. In addition, management continues to aggressively contain costs, direct resources to priority programs and work towards building stockholder value. We appreciate our stockholders` continued support."

Gruß Fraktal
Viragen Completes $5.5 Million Debt Financing

PLANTATION, Fla., Jul 1, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) today announced that it has completed the sale of $5.55 million in secured convertible debentures to an investment group that includes current institutional stockholders. The Company intends to use the proceeds to progress with its business plan to commercialize its portfolio of healthcare technologies including Multiferon(TM), Avian Transgenic Production Technology and Oncology Projects.

After original issue discount, commissions and expenses, the Company received approximately $4.55 million in net proceeds. The debentures, issued under an original issue discount, bear interest at the rate of 10% per annum and have a maturity date of September 1, 2005. The debentures are convertible into shares of Viragen common stock at the option of the Company at a fixed price of $0.32 per share if the market price exceeds $0.42 per share. The debentures may be converted at any time, in whole or in part, at the option of the investors at $0.32 per share. The conversion price, which represents a 125% premium to the volume weighted average price of Viragen`s common stock over a ten day period prior to the closing, is not subject to any price resets. The complete terms of the financing will be detailed in a registration statement to be filed with the Securities and Exchange Commission.

Viragen`s Chairman, Mr. Carl Singer, stated, "This debt funding enables Viragen to continue to move forward with its commercial and scientific initiatives which are aimed at building stockholder value. We have significantly cut our cash burn rate in order to direct monies raised to priority activities and our goal remains to further strengthen the Company`s financial position as we strive to attract additional key funding and partnering opportunities. With adequate financing in place, we expect to report important milestone achievements which validate the exciting market potential of our innovative healthcare products."

"The quality of Viragen`s team, its products and its world-class collaborative partners have compelled our group to remain committed to ensuring that the company is appropriately capitalized," stated investor spokesperson, Mr. Andrew Reckles, General Partner of Palisades Master Fund LP. "We are impressed by Viragen`s immediate ability to offer Multiferon(TM) as a rescue therapy for the many patients that have failed previous interferon treatments for diseases such as hepatitis C and cancer. Looking forward, Viragen`s Avian Transgenic Technology and anti-cancer targets represent significant market opportunities. Our confidence in Viragen`s future is confirmed by our continued investment."

Gruß Fraktal
Bald schiesst es nach Norden ohne Ende.Müsst euch noch gedulden :D dauert nicht mehr lange. Die, wo verkauften, werden es bereuen :mad: Ich verkaufe meine Anteile unter 2Euro!!! nicht.Schaut euch mal den 10-Jahres Chart an!Nach Süden kann es nicht mehr gehen,es ist abgesichert :eek: Die werden noch mit INTERFERON-Multiferon gute Geschäfte machen:D CHAPTER 11 kanns auch nicht mehr kommen Finanziel abgesichert.Also cool bleiben abwarten GEDULD zahlt sich aus:D demnächst müssten Neuigkeiten kommen. Gruss
sehe ich genauso, neuikeiten stehen kurz bevor.
die 5,5mio usd benötigt man sicherlich für die markteinführung der bahnbrechenden medikamente gegegen krebs+seuchen+atemwegserkrankungen und etliche mehr.
1+2 EURO Kursziel nach so einer meldung ist nichts außergewöhnliches !
Bei Viragen kommt heute offensichtlich wieder Bewegung in den Kurs. Nachdem es zunächst bis 0,21 US$ runterging, liegt der Kurs aktuell bei 0,26 US$ bei relativ hohem Volumen. Eine Nachricht habe ich nicht gesehen, aber das kann ja noch kommen.

Gruß Fraktal
Da hast Du vollkommen recht!:D NEWS vorhanden:;) News: VRA

DJ Nine Quarantined In Texas As Anti-SARS Precaution -Report

07/11/2003
Dow Jones News Services
(Copyright © 2003 Dow Jones & Company, Inc.)



NEW YORK (Dow Jones)--Nine people have been quarantined at home near Abilene, Texas, as a precaution against severe acute respiratory syndrome, the Austin American-Statesman reported Thursday on its Web site.

The group includes military personnel who recently passed through the Toronto airport - some of whom reported mild to moderate respiratory problems this week after returning to Texas - and some people they`ve come in contact with, the report said, citing Capt. David May of Dyess Air Force Base in Abilene.

The report said none have been hospitalized and only one person fits the definition of having a suspected case of SARS.

The report cited officials with the Abilene-Taylor County Public Health District as saying no one in the group has been diagnosed with SARS and the public has no reason to be alarmed.

May declined to say exactly when the military personnel were in Toronto or how many were in the group, the report said. The health district said they were in the Toronto airport for about an hour on their way to and from a military exercise in Ontario, the American-Statesman reported.

-By Steven C. Higgins, Dow Jones Newswires; 1-201-938-4378; globaldesk@dowjones.com


(END) Dow Jones Newswires

07-11-03 1104ET

DJ Quarantined/Texas/SARS -2: Test Results Expected In Days



Cable News Network reported Friday that the results of the group`s SARS tests are expected in the next few days.

The CNN report said the group includes six active-duty Air Force personnel and three family members. It said one of the nine recently returned from Canada and became ill with cold-like symptoms.

A CNN reporter said she was told by U.S. Centers for Disease Control that if the cases do turn out to be SARS - "a big if," she said - it could lead to the reinstatement of a warning against travel to Canada. The report said Canadian health officials and U.S. Department of Defense officials held a conference call Friday morning to discuss the matter.

-By Steven C. Higgins, Dow Jones Newswires; 1-201-938-4378; hbsglobaldesk@dowjones.com


(END) Dow Jones Newswires

07-11-03 1119ET kommt langsam ins laufen !!!! GRUSS
was denn für news??
meinst du weil jetzt wieder SARS-Verdacht besteht, werden Biotech-Firmen mit SARS-Medik.Patenten attraktiver.
Ein bisschen makaber, oder. Aber wie das immer so ist, wird geld an leiden anderer verdient. pfui !!
möchte lieber news hören, über markteintritt von medik., was bei viragen kurz bevorsteht.
das sind NEWS !!!
VRA is just about ready to move up to its next platform price of .50 to $2.00 beginning as early as this week. Look for higher volume to confirm e.g.100 to 500 million shares, IMHO.........lots of good news in the pipeline with a major surprise or two may occur. Do your own DD boys and girls - we`ve done ours for the past 4 years. Let the party begin.

gruss
:kiss:
bomastik! are you american? Do you have some special news or informations in mind. I`am convinced in viragen as well, but which surprise do you mean?
die 5,5mio usd, aus akt.verkauf werden höchstwarscheinlich für den martkeintritt eines medik. gebraucht.
bin gespannt wann endlich die news kommen. ist eigentlich höchste zeit. ein so guter einstiegskurs wird nicht mehr wieder kommen.
strong buy ! KRASS KAUFEN !!!!
Heute 45% Kursanstieg auf aktuell 0,29 US$. Hier die Meldung dazu:

Viragen Comments on Interferon Study Which Demonstrates Anti-Cancer Activity

PLANTATION, Fla., Jul 23, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) today commented on a Japanese interferon study from the July 17th online issue of Nature ( http://www.nature.com ). Viragen`s research and development team believes the study further confirms the potential of treating many forms of cancer with its natural human alpha interferon drug, Multiferon(TM).

The research article titled, "Integration of interferon-alpha/beta signaling to p53 responses in tumor suppression and antiviral defense", reports that interferon activates the tumor-suppressor gene called p53. The researchers found that the joint activity of interferon and p53 induced programmed cell death (apoptosis) in cancerous cells and in antiviral immune responses. The p53 gene has been the subject of extensive worldwide research for several years and is regarded as a common denominator in human cancer. The authors concluded that their study suggested the possible usefulness of treating human cancers with interferon in combination with chemotherapeutic drugs that activate p53.

"These are exciting findings which could explain why we are achieving positive results in treating certain cancers with natural alpha interferon," stated Professor William Stimson, Viragen`s Director of Research (Emeritus). "We have conducted several studies utilizing our leukocyte-derived interferon for the treatment of certain cancers, including malignant melanoma. Our results have been encouraging and suggest a strong trend toward increased overall survival along with natural interferon demonstrating an excellent safety and toxicity profile. This new Japanese study may well point to the reason for the potent anti-tumor activity of interferon and suggest new combined therapeutic regimens for treating many forms of malignant disease."

Produced by human white blood cells, alpha interferon is a protein that occurs naturally in the body and helps improve the body`s natural defenses by preparing it to fight viruses and attack and slow the growth of tumors. Since the action of alpha interferon is directed at the cell itself, its anti-viral and anti-cancer functions are extremely broad-ranging, making it a potential therapy for a wide range of diseases.

Dr. Karen Jervis, Viragen`s Director of Technology and Projects Coordinator, discussed some of the advantages that might be offered by a natural human alpha interferon therapy. "The worldwide interferon market is dominated by recombinant (synthetic) interferons which are prescribed for a variety of viral and malignant diseases such as hepatitis C and cancer. Despite being the prevalent therapy, many patients do not benefit when treated with recombinant interferon. It is widely reported that a significant percentage of these patients form unfavorable immune responses that reduce the effectiveness of the therapy and/or may be unable to tolerate the adverse side effects often associated with treatment. This can lead to a lack of compliance and/or withdrawal from treatment and increased costs. It seems advantageous to offer these patients a natural alpha interferon as a `rescue therapy` that closely mimics the human immune system`s natural defensive response while offering a more favorable side effect profile. Furthermore, natural alpha interferon offers multiple subtypes of interferon which may work together as a `cocktail-in-one`, while recombinant versions only exhibit a single subtype." Viragen offers Multiferon(TM) at a cost which is competitive with recombinant interferon regimens.

Background:

The majority of alpha interferons that are marketed are single-subtype recombinant interferons. Therapy resistance is not unusual with recombinant interferons with a significant percentage of patients failing to respond to standard therapy. In some instances, recombinant interferon is rejected by the patient`s immune system, usually caused by the formation of neutralizing antibodies which may lead to a loss of clinical efficacy. Also, many patients cannot tolerate the adverse side effects sometimes associated with recombinant therapy. High doses of recombinant interferon may cause serious, even life- threatening side effects.

Multiferon(TM) - The Natural Choice

Viragen has observed that in many cases, especially when higher dosages are required, its natural interferon appears to offer many advantages to therapy with recombinant interferons.

* Natural alpha interferon is very similar to interferon secreted by the
human leukocytes during a normal virus infection, significantly lowering
the risk of the drug being rejected.
* Natural alpha interferon contains the multiple subtype composition that
is characteristic of interferon produced by the human body. It is
believed that this results in a broader spectrum of specific anti-viral
and immunoregulatory activity with the subtypes acting synergistically
to give a wide-ranging response.
* Natural alpha interferon is significantly less immunogenic than
recombinant interferon and does not cause the formation of neutralizing
antibodies. It is far better tolerated by patients with fewer side
effects and thus allows for higher doses to be administered to maximize
the benefits of the therapy.

Gruß Fraktal
mein "siebter" sinn hat mich wieder mal nicht enttäuscht, und der sagt mir, wir kommen schnell wieder auf den kurs von USD 2,50 !
Viragen ist weltweit No. 1 auf dem Gebiet von natürl. Interferon gegen Krebs, Hep.C, Aids, usw.
Heute gehts wieder los !
Hallo Siebtesinn,könntest du mir den Bericht vom 23.7 in deutsch kurz erläutern?Danke
EquityOutlook.Com Announces Stock Evaluation Ratings for Intel, Viragen Inc., Amgen, JP Morgan, NVIDIA

SHREVEPORT, La., Jul 28, 2003 (BUSINESS WIRE) -- EquityOutlook.Com makes these short-term stock recommendations:

Intel (NASDAQ:INTC) - SELL
Viragen Inc (AMEX:VRA) - BUY
Amgen (NASDAQ:AMGN) - SELL
JP Morgan (NYSE:JPM) - SELL
NVIDIA (NASDAQ:NVDA) - STRONG BUY

WHAT THESE RATINGS MEAN:

EquityOutlook.Com ranks stocks with a proprietary unbiased system of technical analysis. These ratings do not indicate a "long term" view of any company listed. These are ratings that reflect our opinion of a stock`s potential price movement over the next five to ten trading sessions. The stock ratings range from +10 (which indicates our view that a stock has a great chance to move higher) to -10 (which indicates our belief that a stock has a great chance to move lower). These ratings may change based on daily market conditions.

Gruß Fraktal
das Baby sollten wir mal ganz ruhig laufen lassen, obwohl mich die Aktienanzahl ein wenig verschreckt...:)
Der Viragen Kurs erinnert irgendwie an eine gespannte Feder. Bei der kleinsten Meldung geht es rasant nach oben. Wenn die Anleger dann die news genauer studiert haben, kommt in der Regel wieder Verkaufsdruck auf und ein grosser Teil des Gewínns ist wieder dahin. Es fehlt bisher eben wirklich die Nachricht von einem wesentlichen Fortschritt bei der Protein Gewinnung durch das goldene Ei oder über die erwartetete Kooperation. Es ist aber auch klar, dass der Kurs massiv explodieren wird, wenn es denn tatsächlich eine solche Meldung gibt. Das ist klar aus den Kursreaktionen zu ersehen, denn jeder hat Angst, einen solchen Anstieg dann zu verpassen und springt sicherheitshalber schnell auf den Zug auf, wenn er irgendeine news über Viragen liest.

Heute immerhin +9% auf 0,25 US$.

Es bleibt extrem spannend !!!

Gruß Fraktal
Es sieht so aus,als wenn sich die Amis langsam eindecken?oder was habt Ihr für eine Meinung?
VIRAGEN VERSTÄRKT BRETT
- neuer Direktor Adds Pharmaceutical, Wall Street und zugelassene Erfahrung


PLANTAGE , FLORIDA? Juni 25, 2003? Viragen, Inc. (Amex: verkündete heute die Verabredung des Herrn. C. Richard Stafford zu seiner Direktion. Herr Stafford holt über 40 Jahre Managementerfahrung vom zugelassenen, pharmazeutischen und Investitionbankwesen.

Herr Stafford war ein Vizepräsident verantwortlich für Fusionen und Erwerb für Carter-Wallace-Wallace, Inc., ein ehemaliges neues York, die Börse internationales pharmazeutisches verzeichnete, Diagnose und Toilettenartikelfirma. Carter-Wallace-Wallace zahlte Dividenden für rüber hundert Jahre bis seinen Erwerb 2001 für mehr als $1,1 Milliarde. Er wurde in das Umstrukturieren und Verkauf der Firma miteinbezogen, die die Trennung der Verbraucherprodukte von den pharmazeutischen Geschäften umfaßte.

Vor dem Verbinden von Carter-Wallace-Wallace, Herr. Stafford war Präsident von Caithness Corporation, ein Öl-, Gas- und Mineralerforschungunternehmen. Diesmal unterrichtete er auch Abendkurse in neuem York Gesetz Schule. Er hat auch als Vizepräsident der Unternehmensfinanzierung am globalen Investmentbanker, Bär Stearns, sowie den Direktor der korporativen Entwicklung der Firma Bristols-Myers und als Teilnehmer bei Milbank, Tweed gedient , Hadley U. McCloy. Er ist a mit laudeabsolvent von Harvard Hochschule und ein Absolvent von Harvard Gesetz Schule.

?Richard Stafford ist eine hervorragende Hinzufügung zur Direktion Viragen?s und holt beträchtliche Erfahrung von helfenden LeitungWelt-kategorienorganisationen in den Industrien, die direkt auf unserem Geschäft? angegebener Vorsitzender Viragen?s, Herr Carl Singer bezogen werden. vorwärts zum Arbeiten mit ihm, wie wir fortfahren, die kommerziellen und wissenschaftlichen Strategien einzuführen, die entworfen werden, um Aktionärwert zu errichten?

Herr angegebenes Stafford?As eine auftauchende biotechfirma, die sein Drogeverkaufsprogramm einleitet und eine Mappe der Technologie hat, die vielversprechend weiterkommt, Viragen stellt eine besonders aufregende Gelegenheit dar. Ich schaue vorwärts, bearbeitend nah mit dem Brett in helfendem Führer diese Firma, um als eine der Auslese in dieser schwierigen Industrie zu entwickeln?

Es wurde auch heute verkündet, daß Dr. Douglas Lind sich freiwillig erboten hat, seine Aufgaben als Teil des fortwährenden Umstrukturierenprogramms Viragen?s neu zu definieren, um Kosten zu enthalten. Das Brett freute sich, sein Angebot anzunehmen, um als Berater jetzt zu dienen und riet in den Angelegenheiten für korporative Strategie. Des Remains des Dr. Lind, der am Arbeiten mit Brett Viragen?s und älteres Management auf Angelegenheiten festgelegt wurde, bezog auf Finanzierung, geschäftliche Entwicklung und anderen strategischen Tätigkeiten. Er bleibt ein Mitglied des Brettes und fügt wertvolle Erfahrung von seiner ehemaligen Rolle hinzu, während älterer Biotechnologieanalytiker vom Führen von Wall Street Morgan Stanley und PaineWebber fest macht.

In anderem Brett bezogene Nachrichten, wurde es verkündet, daß Herr Bryan König von der Direktion Company?s abgefunden hat.

Über Viragen Inc..
PLANTAGE , FLORIDA? Juli 23., 2003 - Viragen, Inc. (Amex: heute kommentiert eine japanische Interferonstudie von der on-line-Ausgabe Julis 17. der Natur ( http://www.nature.com ). Forschungs- und Entwicklungsmannschaft Viragen?s glaubt, daß die Studie weiter das Potential des Behandelns vieler Formen des Krebses mit seiner natürlichen menschlichen Alphainterferondroge, Multiferon ? bestätigt.

Der Forschungsartikel betitelt?Integration von interferon-alpha/beta, das zu den Antworten p53 im Tumorausgleich und Antivirensignalisiert, verteidigung?, Reports, daß Interferon das Tumor-Entstörergen aktiviert, benannten p53. Die Forscher fanden, daß die gemeinsame Tätigkeit von Interferon und von p53 programmierten Zellentod (apoptosis) in den cancerous Zellen und in den immunen antiviralantworten verursacht. Das Gen p53 ist das Thema der umfangreichen weltweiten Forschung für einige Jahre gewesen und wird als allgemeiner Nenner im menschlichen Krebs betrachtet. Die Autoren stellten fest, daß ihre Studie die mögliche Verwendungsfähigkeit des Behandelns der menschlichen Krebse mit Interferon im Verbindung mit chemotherapeutischen Drogen vorschlug, die p53 aktivieren.

sind aufregende Entdeckungen?These, die, warum wir positive Resultate, wenn wir erzielen bestimmte Krebse mit natürlichem Alphainterferon behandeln? angegebenen Professor William Stimson, Direktor Viragen?s erklären konnten der Forschung (Emeritus). haben einige Studien geleitet, die unser Leukozyte-abgeleitetes Interferon für die Behandlung bestimmter Krebse, einschließlich des bösartigen melanoma verwenden. Unsere Resultate haben eine starke Tendenz in Richtung zu erhöhtem gesamtem Überleben zusammen mit dem natürlichen Interferon angeregt und vorschlagen, das ein ausgezeichnetes Sicherheits- und Giftigkeitprofil zeigt. Diese neue Japanerstudie kann Punkt zum Grund für die starke Antitumortätigkeit von Interferon hervorquellen und neue kombinierte therapeutische Regierungen für das Behandeln vieler Formen der bösartigen Krankheit vorschlagen?

Produziert durch menschliche weiße Blutzellen, ist Alphainterferon ein Protein, das natürlich im Körper auftritt und Hilfen die natürliche Verteidigung der body?s verbessern, indem sie ihn vorbereiten, um Viren zu kämpfen und das Wachstum der Tumoren in Angriff zu nehmen und zu verlangsamen. Da die Tätigkeit von Alphainterferon an der Zelle selbst verwiesen wird, sind seine Antiviren- und krebsbekämpfenden Funktionen extrem die ausgedehnt-Erstreckung und bilden es eine mögliche Therapie für eine breite Strecke der Krankheiten.

Dr. Karen Jervis, Direktor Viragen?s der Technologie und des Projektkoordinators, besprach einige der Vorteile, die durch eine natürliche menschliche Alphainterferontherapie angeboten werden konnten. wird weltweiter Interferonmarkt des?The durch recombinant (synthetisches) Interferon beherrscht, die für eine Vielzahl der Viren- und bösartigen Krankheiten wie Hepatitis C und Krebs vorgeschrieben werden. Trotz des Seins die überwiegende Therapie, fördern viele Patienten nicht, wenn sie mit recombinant Interferon behandelt werden. Es wird weit berichtet, daß ein bedeutender Prozentsatz dieser Patienten ungünstige immune Antworten bilden, die die Wirksamkeit der Therapie verringern und/oder nicht imstande sein können, die nachteiligen Nebenwirkungen zuzulassen, die häufig mit Behandlung dazugehörig sind. Dieses kann zu einen Mangel an Befolgung und/oder Zurücknahme von der Behandlung und von erhöhten Kosten führen. Es scheint vorteilhaft, diesen Patienten ein natürliches Alphainterferon als?rescuetherapie anzubieten? das ahmt nah die natürliche defensive Antwort der menschlichen immunen system?s beim Antrag eines vorteilhafteren Nebenwirkungprofils nach. Ausserdem bietet natürliches Alphainterferon mehrfache Formationsglieder von Interferon an, denen zusammen arbeiten kann als a?cocktail-in-ein?, wenn recombinant, stellen Versionen nur ein einzelnes Formationsglied aus? Viragen bietet Multiferon an? an Kosten, die mit recombinant Interferonregierungen konkurrierend ist.

Hintergrund:
Die Mehrheit einem Alphainterferon, das vermarktet werden, sind recombinant Interferon des Einzelnformationsgliedes. Therapiewiderstand ist nicht mit recombinant Interferon mit einem bedeutenden Prozentsatz der Patienten ungewöhnlich, die auf Standardtherapie reagieren nicht können. In einigen Fällen wird recombinant Interferon durch das immune System des Patienten zurückgewiesen, normalerweise verursacht durch die Anordnung der neutralisierenden Antikörper, die zu einen Verlust der klinischen Wirksamkeit führen können. Auch viele Patienten können nicht die nachteiligen Nebenwirkungen zulassen, die manchmal mit recombinant Therapie dazugehörig sind. Hohe Dosen von recombinant Interferon können die ernsten, sogar lebensbedrohenden Nebenwirkungen verursachen.

Multiferon? - Die Natürliche Wahl

Viragen hat beobachtet, daß in vielen Fällen, besonders wenn höhere Dosierungen angefordert werden, sein natürliches Interferon scheint, viele Vorteile Therapie mit recombinant Interferon anzubieten.

· Natürliches Alphainterferon ist dem Interferon sehr ähnlich, das durch die menschlichen Leukozyten während einer normalen Virusinfektion abgesondert wird und erheblich senkt die Gefahr der Droge, die zurückgewiesen wird.

· Natürliches Alphainterferon enthält den mehrfachen Formationsgliedaufbau, der vom Interferon charakteristisch ist, das durch den menschlichen Körper produziert wird. Es wird geglaubt, daß dieses ein ausgedehnteres Spektrum der spezifischen Antiviren- und immunoregulatory Tätigkeit mit den Formationsgliedern ergibt, die synergistisch fungieren, um eine weitreichende Antwort zu geben.

· Natürliches Alphainterferon ist erheblich weniger immunisierend als recombinant Interferon und verursacht nicht die Anordnung der neutralisierenden Antikörper. Es ist weit besseres zugelassen von den Patienten mit wenigen Nebenwirkungen und darf folglich, damit höhere Dosen ausgeübt werden können, um den Nutzen der Therapie zu maximieren
PLANTATION, Fla., Aug. 4 /PRNewswire-FirstCall/ -- Viragen, Inc. today announced that the Company is scheduled to appear as a featured guest on Biotech Today, a New Media Internet radio show carried by World Talk Radio. The program will air live on Wednesday, August 6 from 4:00 p.m. to 5:00 p.m. (Eastern Daylight Time). The live and archived broadcast can be accessed at the following Internet link: http://www.viragen.com

Viragen has been invited on the program to discuss its collaboration with Roslin Institute (Scotland) to develop Avian Transgenic Technology as a biomanufacturing alternative to costly and relatively inefficient bioreactor technologies (Fermentation/Cell culture techniques). The goal of the project is to turn the common chicken into a highly efficient and cost-effective pharmaceutical producer for the large-scale production of recombinant protein- based drugs, such as monoclonal antibodies for the treatment of cancer.

Guests scheduled to appear on the program include: * Robert C. Salisbury, Viragen``s President and CEO. * Dr. Douglas Lind, a Viragen Board Member and former Senior Biotechnology Equity Analyst for Morgan Stanley. * Dr. Helen Sang, Roslin``s Senior Avian Molecular Biologist and Lead Scientist for the Avian Transgenic Project. Dr. Sang is one of the world``s foremost authorities on avian research and the creator of the world``s first transgenic rooster by a non-viral method. Roslin Institute is one of the world``s leading centers for research on farm and other animals and is internationally renowned for their creation of "Dolly the Sheep". About Avian Transgenic Technology

Viragen holds the worldwide exclusive license to commercialize Avian Transgenic Technology as granted by Roslin Institute. This project is designed to substitute chicken eggs for expensive bioreactor vessels presently used in the manufacture of protein-based drugs. Upon the successful completion of this project, flocks of specially produced transgenic chickens would lay virtually unlimited numbers of eggs which would have significant amounts of the target drug in the egg whites. The proportion of protein drugs, including monoclonal antibodies, under development is forecast to be expanding rapidly and manufacturing constraints, including lack of adequate facilities, have been recognized.

About Viragen, Inc.

Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen``s strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of recombinant protein-based drugs, as well as offering Contract Manufacturing for the biopharmaceutical industry.

Viragen is publicly traded on the American Stock Exchange (VRA). Viragen``s majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen``s key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America``s Blood Centers and the German Red Cross.

Viragen, Inc. Corporate Contact: Douglas Calder, Director of Communications Phone: (954) 233-8746; Fax: (954) 233-1414 E-mail: dcalder@viragen.com

The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "expect", "potential", "suggests", "may", "will", "should", "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management``s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company``s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Guests scheduled to appear on the program "Biotech Today" are potentially subject to be replaced, rescheduled or canceled due to unforeseen conflicts.

Photo: http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b AP Archive: http://photoarchive.ap.org/ PRN Photo Desk, 888-776-6555 or 212-782-2840 Viragen, Inc.

© PR Newswire
VIRAGEN ZUM HEUTE ERSCHEINEN AUF BIOTECH

PLANTAGE, FLORIDA? August 4, 2003 - Viragen, Inc. (Amex: heute verkündet dem Firma wird festgelegt, als gekennzeichneter Gast auf Biotech heute zu erscheinen , ein neues Mittelinternet-Radioerscheinen, das durch Radio World Talk getragen wird. Das Programm lüftet Phasen am Mittwoch, Th Augustes 6 von 4:00 P.M.. zu 5:00 P.M. (östliche Sommerzeit). Die Phasen- und archivierte Sendung kann an der folgenden Internet-Verbindung erreicht werden: http://www.viragen.com

Viragen ist auf dem Programm eingeladen worden, seine Zusammenarbeit mit Institut Roslin (Schottland) zu besprechen um VogelTechnologie Transgenic als biomanufacturing Alternative zu den teuren und verhältnismäßig wirkungslosen Bioreaktortechnologien (Fermentation-/Cellkulturtechniken) zu entwickeln. Das Ziel des Projektes ist, das allgemeine Huhn zu einen in hohem Grade leistungsfähigen und kosteneffektiven pharmazeutischen Produzenten für die großräumige Produktion der recombinant proteinbasierten Drogen, wie monoclonal Antikörper für die Behandlung des Krebses zu machen.

Die Gäste, die festgelegt werden, auf dem Programm zu erscheinen, umfassen:

Robert C. Salisbury, Präsident Viragen?s und CEO.

Dr. Douglas Lind, ein Brettmitglied Viragen und ehemaliger älterer Biotechnologiebilligkeitsanalytiker für Morgan Stanley.

Dr. Helen Sang, älterer molekularer Vogelbiologe Roslin?s und Leitungwissenschaftler für das VogelProjekt Transgenic. Dr. Sang ist eine der vordersten Behörden der world?s auf Vogelforschung und dem Schöpfer des ersten transgenic Hahns der world?s durch eine Nichtvirenmethode. Institut Roslin ist eine der führenden Mitten der Welt für Forschung auf Bauernhof und anderen Tieren und ist für ihre Kreation?Dolly der Schafe? international renowned.
Über VogelTechnologie Transgenic

Viragen hält die weltweite ausschliessliche Lizenz, VogelTechnologie Transgenic in den Handel zu bringen, wie von Roslin Institute bewilligt. Dieses Projekt wird entworfen, um Huhneier für die kostspieligen Bioreaktorbehälter zu ersetzen, die momentan in der Herstellung der proteinbasierten Drogen benutzt werden. Nach der erfolgreichen Beendigung dieses Projektes, würden Mengen der besonders produzierten transgenic Hühner die praktisch unbegrenzten Anzahlen von Eiern legen, die bedeutende Mengen der Zieldroge im Eiweiß haben würden. Der Anteil Proteindrogen, einschließlich der monoclonal Antikörper, unter Entwicklung wird prognostiziert, schnell zu erweitern und herstellenbegrenzungen, einschließlich des Mangels an ausreichendem Service, sind erkannt worden.

Über Viragen Inc..
Viragen ist eine Biotechnologiefirma, die auf die Forschung, die Entwicklung und die Kommerzialisierung der natürlichen und recombinant proteinbasierten Drogen sich spezialisiert, die entworfen werden, um eine ausgedehnte Strecke der Viren- und bösartigen Krankheiten zu behandeln. Diese proteinbasierten Drogen schließen natürliches menschliches Alphainterferon, monoclonal Antikörper, Peptiddrogen und therapeutische Impfstoffe mit ein. Strategie Viragen?s umfaßt auch die Entwicklung der VogelTechnologie Transgenic für die großräumige, kosteneffektive Herstellung seiner Mappe der proteinbasierten Drogen, sowie anbietenvertragsherstellung für die biopharmaceutical Industrie.

Viragen wird öffentlich auf der amerikanischen Börse (VRA) gehandelt. Besessene Tochtergesellschaft Viragen?s Majorität, Viragen International, Inc., wird öffentlich auf dem im Freiverkehr gehandelten Anschlagbrett (VGNI) gehandelt. Schlüsselpartner und Lizenzgeber Viragen?s umfassen: Institut Roslin, ErinnerungsKrebsmitte Sloan-Kettering, nationale Institute der Gesundheit, Krebsforschung Großbritannien, Universität von Nottingham (Großbritannien), Universität von Miami, Blutmitten America?s und das deutsche rote Kreuz.


--------------------------------------------------------------------------------

Korporativer Kontakt Viragen, Inc.:

Douglas Calder, Direktor von Kommunikationen
Telefon: (954) 233-8746; Telefax: (954) 233-1414
E-mail: dcalder@viragen.com


--------------------------------------------------------------------------------

Die vorangehende Presseansage enthält das Vorwärts-Schauen der Aussagen, die durch solche Terminologie wie?expect gekennzeichnet
Habe mich bei meiner Bank erkundigt,warum bid u.ask nicht bedient wird.Es werden nur die leeren Felder gefüllt ,da eine Umstellung stattfindet.Die Stückzahl im bid und ask hat nichts zusagen. ES wird in Zukunft so aussehen.
Die Trumpfkarte am 6.8 ????????????????wovon mann in Amerika spricht?????????Eure Meinung dazu!
PLANTAGE, FLORIDA? August 4, 2003 - Viragen, Inc. (Amex: heute verkündet dem Firma wird festgelegt, als gekennzeichneter Gast auf Biotech heute zu erscheinen , ein neues Mittelinternet-Radioerscheinen, das durch Radio World Talk getragen wird. Das Programm lüftet Phasen am Mittwoch, Th Augustes 6 von 4:00 P.M.. zu 5:00 P.M. (östliche Sommerzeit). Die Phasen- und archivierte Sendung kann an der folgenden Internet-Verbindung erreicht werden: http://www.viragen.com
Du solltest die Info. besser durchlesen.Info.in englisch +deutsch.Gruß
bid 8280 ask 18500 wurde von der Börse rein profielaktisch eingegeben lt. meiner Bank,wegen einer Umstellung. Realtime 0,26.
VIRAGEN ZUM HEUTE ERSCHEINEN AUF BIOTECH

PLANTAGE, FLORIDA? August 4, 2003 - Viragen, Inc. (Amex: heute verkündet dem Firma wird festgelegt, als gekennzeichneter Gast auf Biotech heute zu erscheinen , ein neues Mittelinternet-Radioerscheinen, das durch Radio World Talk getragen wird. Das Programm lüftet Phasen am Mittwoch, Th Augustes 6 von 4:00 P.M.. zu 5:00 P.M. (östliche Sommerzeit). Die Phasen- und archivierte Sendung kann an der folgenden Internet-Verbindung erreicht werden: http://www.viragen.com

Viragen ist auf dem Programm eingeladen worden, seine Zusammenarbeit mit Institut Roslin (Schottland) zu besprechen um VogelTechnologie Transgenic als biomanufacturing Alternative zu den teuren und verhältnismäßig wirkungslosen Bioreaktortechnologien (Fermentation-/Cellkulturtechniken) zu entwickeln. Das Ziel des Projektes ist, das allgemeine Huhn zu einen in hohem Grade leistungsfähigen und kosteneffektiven pharmazeutischen Produzenten für die großräumige Produktion der recombinant proteinbasierten Drogen, wie monoclonal Antikörper für die Behandlung des Krebses zu machen.

Die Gäste, die festgelegt werden, auf dem Programm zu erscheinen, umfassen:

Robert C. Salisbury, Präsident Viragen?s und CEO.

Dr. Douglas Lind, ein Brettmitglied Viragen und ehemaliger älterer Biotechnologiebilligkeitsanalytiker für Morgan Stanley.

Dr. Helen Sang, älterer molekularer Vogelbiologe Roslin?s und Leitungwissenschaftler für das VogelProjekt Transgenic. Dr. Sang ist einer der vordersten Behörden der world?s auf Vogelforschung und des Schöpfers des ersten transgenic Hahns der world?s durch eine Nichtvirenmethode. Institut Roslin ist eine der führenden Mitten der Welt für Forschung auf Bauernhof und anderen Tieren und ist für ihre Kreation?Dolly der Schafe? international renowned.
Über VogelTechnologie Transgenic

Viragen hält die weltweite ausschliessliche Lizenz, VogelTechnologie Transgenic in den Handel zu bringen, wie von Roslin Institute bewilligt. Dieses Projekt wird entworfen, um Huhneier für die kostspieligen Bioreaktorbehälter zu ersetzen, die momentan in der Herstellung der proteinbasierten Drogen benutzt werden. Nach der erfolgreichen Beendigung dieses Projektes, würden Mengen der besonders produzierten transgenic Hühner die praktisch unbegrenzten Anzahlen von Eiern legen, die bedeutende Mengen der Zieldroge im Eiweiß haben würden. Der Anteil Proteindrogen, einschließlich der monoclonal Antikörper, unter Entwicklung wird prognostiziert, schnell zu erweitern und herstellenbegrenzungen, einschließlich des Mangels an ausreichendem Service, sind erkannt worden.

Über Viragen Inc..
Viragen ist eine Biotechnologiefirma, die auf die Forschung, die Entwicklung und die Kommerzialisierung der natürlichen und recombinant proteinbasierten Drogen sich spezialisiert, die entworfen werden, um eine ausgedehnte Strecke der Viren- und bösartigen Krankheiten zu behandeln. Diese proteinbasierten Drogen schließen natürliches menschliches Alphainterferon, monoclonal Antikörper, Peptiddrogen und therapeutische Impfstoffe mit ein. Strategie Viragen?s umfaßt auch die Entwicklung der VogelTechnologie Transgenic für die großräumige, kosteneffektive Herstellung seiner Mappe der proteinbasierten Drogen, sowie anbietenvertragsherstellung für die biopharmaceutical Industrie.

Viragen wird öffentlich auf der amerikanischen Börse (VRA) gehandelt. Besessene Tochtergesellschaft Viragen?s Majorität, Viragen International, Inc., wird öffentlich auf dem im Freiverkehr gehandelten Anschlagbrett (VGNI) gehandelt. Schlüsselpartner und Lizenzgeber Viragen?s umfassen: Institut Roslin, ErinnerungsKrebsmitte Sloan-Kettering, nationale Institute der Gesundheit, Krebsforschung Großbritannien, Universität von Nottingham (Großbritannien), Universität von Miami, Blutmitten America?s und das deutsche rote Kreuz.
In Amerika spricht mann von einer Trumpfkarte
ebihard:
du bist auch so engagiert in viragen, wie ich es bin.
heute wird das radio-live-interview den durchbruch für viragen bedeuten. zum einen werden weitere pharma/industrie-unter. auf viragen aufmerksam, zum anderen könnte viragen die gunst der stunde nutzen um einige medik.releases bekannt zu machen.
wird auf jeden fall, sehr sehr spannend heute.
drücken wir die daumen.
Kurs steigt heute wieder etwas an. Ob diese news dafür der Grund sind ? Wird wohl eher wieder ein kurzer Hype werden, da es nur um eine der üblichen Ankündigung einer Präsentation geht.

Viragen To Present On Biotech Webcast

PLANTATION, Fla., Sep 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) today announced that the Company is scheduled to appear as a featured presenter as part of the Informed Investors Biotechnology/Healthcare Virtual Forum. The webcast presentation is scheduled for Tuesday, September 9 at 9:00 a.m. (Eastern Daylight Time). The live and archived broadcast can be accessed at the following Internet link: http://www.viragen.com

Fraktal
Wird sicher interessant zu sehen, ob Viragen vor der wieder aufflammenden Angst vor SARS profitieren kann.

Fraktal
Aus der FAZ vom 29.12.2003 über das erneute Auftreten von SARS:

Ein biopolitischer Schreckschuß
Sars und das globale Knalltrauma: Das Virus will nicht weichen

..... Die Behandlung mit einer Kombination aus Interferon Alpha und Kortikosteroiden hat die Überlebensrate der Patienten deutlich erhöht - und zumindest in vielen Kliniken die Todesangst gebannt.


Zur Erinnerung von der Viragen Homepage:
http://www.viragen.com/multiferon.htm#multiferon
Multiferon is a highly purified, multi-subtype, natural human alpha interferon derived from human white blood cells, a central component of the body’s immune system. It has been studied in more than 1600 patients in clinical and supporting studies, including hepatitis C, malignant melanoma and other cancers ....

Fraktal
Viragen hat wieder einen Investor gefunden, der Viragen Aktien gekauft hat. Damit hat man die Finanzierung bis ins Jahr 2005 gesichert. Der Kurs reagiert verhalten positiv: aktuell 0,26 US$ (+0,01 US$)

Viragen Announces New Round Of Equity Financing

PLANTATION, Fla., Dec. 30 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the biotechnology Company received approximately $4.2 million in a sale of its common stock and warrants completed with a group of new and returning institutional investors. The Company intends to use the proceeds to commercialize its lead drug, Multiferon(TM), and further the research and development of its portfolio of healthcare technologies.

"I expect to report that our calendar year-`end balance sheet has significantly improved," stated Dennis W. Healey, Viragen`s Chief Financial Officer. "Based on Senior Management`s efforts to cut overhead and operating costs this year, this funding strengthens our cash position to provide working capital into 2005 as we execute our business plan. Also, I believe our financial position has been further strengthened this quarter through the conversions of all outstanding debentures related to previous financings thus eliminating that debt. Our solidified financial foundation should prove advantageous as we continue to seek to attract new partners and investors."

The complete terms of financing will be filed via a Form 8-K with the Securities and Exchange Commission (SEC). The document will be available at the SEC`s website at http://www.sec.gov and Viragen`s website at http://www.Viragen.com

Fraktal
Tut sich ja im Moment recht wenig um Viragen.
Weiß jemand ob Multiferon schon eine Zulassung in Europa erhalten hat ?
Habe auf der Homepage nichts von EU-Staaten gesehen.

tasmandevil
Viragen To Present At Friedland Capital Event

PLANTATION, Fla., Jan. 13 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Company is scheduled to present at Friedland Capital`s Biotech Luncheon on Wednesday, January 14th. A select audience of brokers, analysts, fund managers and institutional investors will be in attendance, by invitation only.

Event: Friedland Capital`s Biotech, Medical & Healthcare Luncheon
When: 12:00 p.m. (EST), January 14, 2004
Where: Maggiano`s (21090 St. Andrew`s Blvd), Boca Raton, Florida
For: Qualified members of the financial community
To RSVP: 800-313-1989 or visit
http://www.friedlandcapitalevents.com/attend.htm

Fraktal
wurde wirlich mal zeit, hoffe die alten hasen melden sich hier wieder, nachdem finanztreff dicht gemacht hat
bin mal auf morgen gespannt !!!! :laugh: :laugh: :laugh:
(alias Bladetrader)
Das Interesse hat inzwischen hier in Deutschland so stark nachgelassen, dass Viragen bereits 15% unter dem Umrechnungskurs von Dollar in Euro Wert gehandelt wir. In USA: 0,26 US$, bei uns 0,18 €, Euro Kurs: ca 1,255 $. Stark !!

Fraktal
Jaja Finanztreff,

war das noch schön mit Bladetrader zu streiten.

Die Pappnasen haben die Community ohne Vorwarnung geschlossen.

:mad:
S.
ich denke mal, dass wir uns endlich mal wieder ein 2.arschloch freuen duerfen (mal ganz flappsig ausgedr.) "eintritt in den chin.markt" = "pot.partner|abnehmer" , wenn das nicht geil klingt. SARS ist ausserdem wieder auf d. vormarsch. weiss zwar nicht, ob nat. multiferon auch huehnerpest-resistenz ist, aber die spekulationen sind allemal da !
flopp heute mal ueber die 0.30 VIRAGEN !!!!!!!!
gruss an alle die viragen treu geblieben sind
(alias bladetrader)
...
siebtesinn

ich übersetze deine Ausführungen so, als ob du mit einem
Ausbruch von Viragen rechnen würdest. Wenn das so wäre,
müsste das Handelsvolumen bedeutend höher liegen.
Nichts desto trotz, bewerte auch ich Viragen sehr gut,
mit viel Spielraum für den Kurs nach oben, wenn auch etwas
Geduld gefragt ist.

...
was ist denn los mit dir trojas, du redest immer so, als wenn dir was im popo steckt ! du muss mal lockerer werden, immer dieses spiessige formulieren. das niveau kann man ja trotzdem halten ! das nervt mich schon die ganze zeit !
nur ein nett gemeinter rat :D
Viragen To Present At Chinese Business Forum

PLANTATION, Fla., Jan. 21 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Company is scheduled to participate as part of a Chinese pharmaceutical roundtable titled, "Doing Business in China: The Chinese Healthcare Markets - Potentials and Obstacles." The event will take place in South Florida and is sponsored by Genesis Technology Group, Inc.(NASDAQ-OTCBB:GTEC) , a business development firm that fosters bilateral commerce between companies in the United States and Europe with those in China. The presentation by Viragen and Genesis will cover an overview of Chinese pharmaceutical market experiences.

Viragen is working with Genesis Technology Group to introduce Multiferon(TM) to potential distribution partners in China. Multiferon is currently approved for sale in Hong Kong as a second-line therapy for the treatment of Hairy Cell Leukemia and Chronic Myelogenous Leukemia, and the registration process is underway throughout Asia to expand the drug`s approved indications to include many viral and malignant diseases including hepatitis B, hepatitis C and certain cancers.

Event: Doing Business in China: China Pharmaceutical Roundtable
Topic: The Chinese Healthcare Markets - Potential and Obstacles
When: 3:00 p.m. - 5:30 p.m. (EST), February 5, 2004
Where: Renaissance Hotel (1230 S. Pine Island Rd.), Plantation, Florida
Fee: There is no fee for this event, but space is limited
To RSVP or obtain the program`s agenda: contact Melanie Eckenroth at
(561) 988-9880 or via email to: Melanie@genesis-technology.net

Fraktal
:confused: :confused: :confused: :confused:
Hallo

sind die alten kämpfer vom Finanztreff wieder hier?

weiß auch nicht was ich machen soll.
Hat sich das Warten doch gelohnt:)
Hängt bestimmt mit den 5 Febuar zusammen da wissen wieder einige mehr im vorraus:)
Ja, was ist am 5.Feb?
Und: Diese Presentations auf irgendwelchen Boards gibt´s alle Naslang. Da braucht man nicht viel drauf geben. Man muss gut aufpassen. Denn diese kleine Aktie fällt immer überaus flott in sich zusammen. Ich erinnere mich nur ungern noch jener Tage, als ich das amerikanische Yahoo-Board zu VRA so´n bißchen mitlas. Ein Graus. Man hatte den Eindruck, dass sich hauptsächlich paranoide Deppen in dieser Aktie / diesem Board aufhielten. Was überwiegt, wird sich zeigen. Der Kurs wird jedenfalls ganz klar bei den Gestörten gemacht.
hey guys,

ja war ein finanztreff.ler :-)
jetzt melden sich die leute wieder, erst wenn der kurs steigt. die leute wollen die chance nicht verpassen und sind guter dinge, was am 05.02. bekanntg. wird. vielleicht sogar ein mittelchen gegen hühnerpest. mit hühnern haben dieja bereits zutun !
#89

Bladetrader, zu Zeiten von Finanztreff, so kurz vor Schließung der Community, hattest Du doch eine Kiste voll Info Material bekommen.
Was ergab die Auswertung ?

Bye
S.
Aus Sicht des Charts steht eine wichtige Entscheidung an. Gelingt der Ausbruch über das alten Schlußkurs-Hoch von 0,38 US$, könnte es deutlich aufwärts gehen. Ich vermute allerdings eher das `normale` Verhalten. Wenn die morgige Präsentation gelaufen ist, geht es wieder abwärts, weil doch nichts Neues kommt.

gelb: 38-Tage Linie, grün: 200-Tage Linie


Fraktal
Vorbörslich steht Viragen bei 0,31 US$, also 1 cent höher als der Schlußkurs gestern. Umgerechnet macht das 0,26 €. In Frankfurt steht der Briefkurs bei 0,24 €, also eine günstige Gelegenheit für Leute, die von der Viragen Story überzeugt sind.

Fraktal
@straight , die firma wurde nochmal im einzelnen vorgestellt, mit den einzelnen quartals-zahlen, die zukunfts-visionen erlaeutert, usw.
also fuer uns ist das nichts neues. aber hab das damals nur angefordert, weil ich jem. aus der pro7-redaktion kenne, und ihn gefragt habe, ob er das nicht mal bei einem red.meeting vorschlage koenne fuer eine bio-doku ! ist doch super-interess. erst dolly geklont, dann huehner gen-manipul., deren eier uns gesund machen :-)



VRA hat in den 20 Jahren in denen sie nun an der Börse notiert sind, erst 1 x Gewinne ausgewiesen, aktuell sind sie mit fast 100 Mio. USD bewertet, anscheinend billigen die Investoren dem Unternehmen ausgezeichnete Chancen zu, obwohl nahezu Null Umsätze generiert werden.

Ob der Durchbruch gelingt kann wahrscheinlich aus heutiger Sicht keiner beurteilen, dementsprechend hoch sind auch die Risiken in dem Wert.


Hier gibt´s eine Elliott-analyse zu VRA, allein die Tatsache dass bei einem Pennystock mit Elliott gearbeitet wird zeigt m.E. dass sich hauptsächlich Zocker in dem Wert tummeln. Sollte sich die Prognose mit 40 bis 60 cent bewahrheiten, nehme ich den Gewinn natütlich gerne mit. :)

http://www.members.shaw.ca/durantec/reports/VRA1.pdf
hier noch ein beeindruckendes Beispiel welche Gestörten aus den USA derzeit VRA Aktionäre sind :

MOON URANUS IS OUT TONIGHT
by: stinkyhiney
Long-Term Sentiment: Buy 02/08/04 10:39 pm
Msg: 198025 of 198033

Can you smell what I am cooking GO VRA GOGO NOW because I need the PENNY Now smell DAT!

-------------------------------------------------------

my long term 500k investment
by: city148
Long-Term Sentiment: Strong Buy 02/08/04 09:01 pm
Msg: 198016 of 198033

could bring me in the millions
hey leuts.
ich war auch schonmal bei viragen investiert.
und zwar beim letzten hype (auch wenn ich damals nicht mehr daran geglaubt hätte und kurz vorher schon verkaufen wollte....)
aber das ist jetzt alles schnee von gestern.
WKN: 500770
hier ist der hype mitten im gange.
wenn jemand interesse hat.
gucken kostet nichts.

ps: ich poste das hier nur weil in diesem thread sowieso nur spekulative investoren sind und nach solchen aktien suchen...

viel erfolg bei euren trades!
sorry, mein fehler....
falsche WKN gepostet
richtige ist:
WKN: 906757 singua biotech
diese News könnten Viragen wieder über 1 USD hochpushen.


10-Q: VIRAGEN INC


Recent Developments

In February 2004, we filed a patent application with the British Patent Office covering the use of natural, multi-subtype alpha interferon for human treatment and prevention of avian influenza virus, commonly known as avian flu.

Avian influenza is an infectious viral disease of birds caused by type A influenza strain. The type A influenza group of viruses have certain characteristics that make them of particular concern to the human population. They have a tendency to undergo mutation, resulting in new variants for which no vaccine is available. In addition, such viruses have the potential to combine with viruses from other species, leading to pandemics due to the resulting difficulties in developing effective treatments or preventative measures.

While no studies are currently planned or ongoing, we believe that Multiferon is a prime candidate for evaluation in avian influenza studies. We are contacting those international research organizations which are conducting studies in this area and offering samples of our product for in vitro and human evaluations.

In November 2003, we entered into an agreement with Pentafarma S.A. (Pentafarma) to distribute our natural human alpha interferon, Multiferon, exclusively in Chile. Headquartered in Santiago, Pentafarma is a specialized leader for the distribution of healthcare products related to dialysis and nephrology and is a wholly-owned subsidiary of Fresenius Medial Care, the worlds largest, integrated provider of products and services for chronic kidney failure. Pentafarma believes that Multiferon may offer benefits to a growing segment of its dialysis patients and intends to initially evaluate the use of Multiferon in dialysis patients diagnosed with chronic hepatitis C. The agreement provides that Pentafarma shall take all measures necessary to achieve regulatory approval of Multiferon in Chile.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses. On an on-going basis, we evaluate our estimates, including those related to inventories, depreciation, amortization, asset valuation allowances, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements.

Inventories. Inventories consist of raw materials and supplies, work in


process and finished product. Finished product consists of purified
natural human alpha interferon. Our inventories are stated at the lower of
cost or market (estimated net realizable value). Raw materials and
supplies cost is determined on a first-in, first-out basis. Work in
process and finished product costs consisting of raw materials, labor and
overhead are recorded at a standard cost (which approximates actual cost).
Excess/idle capacity costs are expensed in the period in which they are
incurred. If the cost of the inventories exceeds their expected market
value, provisions are recorded currently for the difference between the
cost and the market value. These provisions are determined based on
estimates. The valuation of inventories also requires us to estimate
excess inventories and inventories that are not saleable. The
determination of excess or non-saleable inventories requires us to
estimate the future demand for our product and consider the shelf life of
the inventory. If actual demand is less than our estimated demand, we
could be required to record inventory reserves, which would have an
adverse impact on our results of operations.
@ Gordon Gekko

woher hast du diese Information????

Gruß bellabella:confused: :confused:
10-Q: VIRAGEN INC

(EDGAR Online via COMTEX) -- Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Factors That May Affect Future Results

This document and other documents we may file with the Securities and Exchange Commission contain forward-looking statements. Also, our company management may make forward-looking statements orally to investors, analysts the media and others.

Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factorsmany beyond our controlthat could cause actual events or results to be significantly different from those described in the forward-looking statement. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong.

Forward-looking statements might include one or more of the following:

anticipated debt or equity fundings;

projections of future revenue;

anticipated clinical trial commencement dates, completion timelines or


results;

anticipated receipt of regulatory approvals;

descriptions of plans or objectives of management for future operations,


products or services;


forecasts of future economic performance; and

descriptions or assumptions underlying or relating to any of the above


items.

Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They use words such as anticipate, estimate, expect, project, intend, plan, believe or words of similar meaning. They may also use words such as will, would, should, could or may.

Factors that may cause actual results to differ materially include the risks and uncertainties discussed below, as well as in the Risk Factors section included in our Form S-3 (File No. 333-112168) filed January 23, 2004 with the Securities and Exchange Commission. You should read them. You should also read the risk factors listed from time to time in our reports on Form 10-Q or 10-K, and registration statements on Form S-1 or S-3 and amendments, if any, to these documents. Viragen will provide you with a copy of any or all of these reports at no charge.

Our business, results of operations and financial condition could be adversely affected by a number of risks and uncertainties, including the following:

whether we are able to secure sufficient funding to maintain our operations, complete clinical trials and successfully market our product;

whether our stock price will enable us to conduct future financings;

whether the efficacy, price and timing of our natural human alpha interferon will enable us to compete with other well established, highly


capitalized, biopharmaceutical companies;


whether clinical testing confirms the efficacy of our product, and results
in the receipt of regulatory approvals. We have not sought the approval of


our natural human alpha interferon product from the U.S. Food and Drug
Administration or its European Union counterparts, except Sweden;


whether our patent applications result in the issuance of patents, or


whether patents and other intellectual property rights provide adequate
protections in the event of misappropriation or infringement by third
parties;

Table of Contents

whether our avian transgenics program will succeed in being able to


produce targeted drugs in egg whites of transgenic chickens in
commercially viable quantities;


whether, despite receipt of regulatory approvals, our products are


accepted as a treatment superior to that of our competitors; and


whether we can generate revenue sufficient to offset our historical losses


and achieve profitability.

Our natural human alpha interferon product was developed and is manufactured overseas in our Swedish facility. Our avian transgenic and oncology programs are also being researched and developed in Europe. Our dependence on foreign manufacturing and expected international sales exposes us to a number of risks, including:

unexpected changes in regulatory requirements;

tariffs and other trade barriers, including import and export


restrictions;


political or economic instability;

compliance with foreign laws;

transportation delays and interruptions;

difficulties in protecting intellectual property rights in foreign


countries; and


currency exchange risks.

Recent Developments

In February 2004, we filed a patent application with the British Patent Office covering the use of natural, multi-subtype alpha interferon for human treatment and prevention of avian influenza virus, commonly known as avian flu.

Avian influenza is an infectious viral disease of birds caused by type A influenza strain. The type A influenza group of viruses have certain characteristics that make them of particular concern to the human population. They have a tendency to undergo mutation, resulting in new variants for which no vaccine is available. In addition, such viruses have the potential to combine with viruses from other species, leading to pandemics due to the resulting difficulties in developing effective treatments or preventative measures.

While no studies are currently planned or ongoing, we believe that Multiferon is a prime candidate for evaluation in avian influenza studies. We are contacting those international research organizations which are conducting studies in this area and offering samples of our product for in vitro and human evaluations.

In November 2003, we entered into an agreement with Pentafarma S.A. (Pentafarma) to distribute our natural human alpha interferon, Multiferon, exclusively in Chile. Headquartered in Santiago, Pentafarma is a specialized leader for the distribution of healthcare products related to dialysis and nephrology and is a wholly-owned subsidiary of Fresenius Medial Care, the worlds largest, integrated provider of products and services for chronic kidney failure. Pentafarma believes that Multiferon may offer benefits to a growing segment of its dialysis patients and intends to initially evaluate the use of Multiferon in dialysis patients diagnosed with chronic hepatitis C. The agreement provides that Pentafarma shall take all measures necessary to achieve regulatory approval of Multiferon in Chile.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses. On an on-going basis, we evaluate our estimates, including those related to inventories, depreciation, amortization, asset valuation allowances, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements.

Inventories. Inventories consist of raw materials and supplies, work in


process and finished product. Finished product consists of purified
natural human alpha interferon. Our inventories are stated at the lower of
cost or market (estimated net realizable value). Raw materials and
supplies cost is determined on a first-in, first-out basis. Work in
process and finished product costs consisting of raw materials, labor and
overhead are recorded at a standard cost (which approximates actual cost).
Excess/idle capacity costs are expensed in the period in which they are
incurred. If the cost of the inventories exceeds their expected market
value, provisions are recorded currently for the difference between the
cost and the market value. These provisions are determined based on
estimates. The valuation of inventories also requires us to estimate
excess inventories and inventories that are not saleable. The
determination of excess or non-saleable inventories requires us to
estimate the future demand for our product and consider the shelf life of
the inventory. If actual demand is less than our estimated demand, we
could be required to record inventory reserves, which would have an
adverse impact on our results of operations.

Table of Contents

Long-lived assets. In accordance with SFAS No. 144, Accounting for the


Impairment or Disposal of Long-Lived Assets, we review our long-lived
assets, including intangible assets, for impairment whenever events or
changes in circumstances indicate that the carrying amount of these assets
may not be fully recoverable. The assessment of possible impairment is
based on our ability to recover the carrying value of our asset based on
our estimate of its undiscounted future cash flows. If these estimated
future cash flows are less than the carrying value of the asset, an
impairment charge is recognized for the difference between the assets
estimated fair value and its carrying value. As of the date of these
financial statements, we are not aware of any items or events that would
cause us to adjust the recorded value of our long-lived assets, including
intangible assets, for impairment.


Goodwill. In accordance with SFAS No. 142, Goodwill and Other Intangible
Assets, goodwill is not amortized. Goodwill is reviewed for impairment on


an annual basis or sooner if indicators of impairment arise. All of our
goodwill arose from the acquisition of ViraNative in September 2001 and
the subsequent achievement of certain milestones defined in the
acquisition agreement. We periodically evaluate that acquired business for
potential impairment indicators. Our judgments regarding the existence of
impairment indicators are based on legal factors, market conditions, and
the operational performance of the acquired business. During the fourth
quarter of fiscal 2003, we completed our annual impairment review of our
goodwill with the assistance of an independent valuation firm. The
impairment review indicated that our goodwill was not impaired. Future
changes in the estimates used to conduct the impairment review, including
revenue projections or the fair market value of Viragen Internationals
common stock, could cause our analysis to indicate that our goodwill is
impaired in subsequent periods and result in a write-off of a portion or
all of our goodwill.


Stock-based compensation. Our employee stock option plans are accounted


for under Accounting Principles Board Opinion No. 25 (APB 25),
Accounting for Stock Issued to Employees, and related interpretations. We
grant stock options for a fixed number of shares to employees with an
exercise price equal to the fair market value of the shares at the date of
grant. In accordance with APB 25, we recognize no compensation expense for
these stock option grants. We account for our stock-based compensation
arrangements with non-employees in accordance with Statement of Financial
Accounting Standards (SFAS) No. 123, Accounting for Stock-Based
Compensation and related guidance, including Emerging Issues Task Force
(EITF) No. 96-18, Accounting for Equity Instruments That Are Issued to
Other Than Employees for Acquiring, or in Conjunction with Selling, Goods
or Services. Accordingly, we recognize as expense the estimated fair value
of such instruments as calculated using the Black-Scholes valuation model.
The estimated fair value is re-determined each quarter using the
methodologies allowable by SFAS No. 123 and EITF No. 96-18 and the expense
is amortized over the vesting period of each option or the recipients
contractual arrangement, if shorter.


Convertible Debt Issued with Stock Purchase Warrants: Viragen accounts for


convertible debt issued with stock purchase warrants in accordance with
APB No. 14, Accounting for Convertible Debt and Debt Issued with Stock
Purchase Warrants, EITF No. 98-5, Accounting for Convertible Securities
with Beneficial Conversion Features or Contingently Adjustable Conversion
Ratios, and EITF No. 00-27, Application of Issue No. 98-5 to Certain
Convertible Instruments. The determination of the relative fair value of
the components of our convertible debentures issued with common stock
purchase warrants requires the use of estimates. Changes in those
estimates would result in different relative values being attributed to
the components, which could result in more or less discount on the
principal amount of the debentures.

Table of Contents

Revenue recognition. We recognize revenue from sales of our natural human alpha interferon product when title and risk of loss has been transferred,


which is generally upon shipment. Moreover, recognition requires
persuasive evidence that an arrangement exists, the price is fixed and
determinable, and collectibility is reasonably assured.


Litigation and other contingencies. We monitor the status of our


litigation and other contingencies for purposes of loss accrual. If we
believed a loss to be probable and reasonably estimated, as required by
SFAS No. 5, Accounting for Contingencies, we would establish an
appropriate accrual. We would base our accruals on information available
at the time of such determination. Information may become available to us
after that time, for which additional accruals may be required.

Liquidity and Capital Resources

As of December 31, 2003, we had on-hand approximately $11,148,000 in cash. As of December 31, 2003, we had working capital of approximately $12,728,000, compared to working capital of approximately $2,475,000 as of June 30, 2003. The increase in cash of approximately $5,205,000 compared to the previous fiscal year end balance was due primarily to approximately $11,915,000 raised through private equity placements and exercises of private placement warrants. Cash used to fund operations during the six months ended December 31, 2003 totaling approximately $5,841,000, included the reduction in our accounts payable and other accrued expenses balance by approximately $881,000. For the six months ended December 31, 2003, capital expenditures included approximately $775,000 related to the build-out of our production facility in Sweden and financing expenditures included the repayment of convertible debentures, short-term borrowings and long-term debt of approximately $483,000.

On December 23, 2003, we sold approximately 22.8 million shares of our common stock to institutional investors at $0.20 per share for an aggregate amount of approximately $4.55 million. In connection with this transaction, we also issued three-year warrants to purchase a total of 6.83 million shares of our common stock at a price of $0.26 per share. In connection with this transaction, we paid approximately $296,000 and issued a warrant to purchase 182,000 shares of our common stock at $0.20 per share as a fee to the finder for this transaction. The exercise prices of these warrants are subject to adjustment downward depending upon future equity transactions.

On September 29, 2003, we sold approximately 21.3 million shares of our common stock to institutional investors at $0.224 per share for an aggregate amount of approximately $4.78 million. In connection with this transaction, we also issued three-year warrants to purchase a total of 4.26 million shares of our common stock at a price of $0.28 per share. In connection with this transaction, we issued 1.4 million shares of our common stock and a warrant to purchase 191,000 shares of our common stock at $0.224 per share as a fee to the finder for this transaction. The exercise prices of these warrants are subject to adjustment downward depending upon future equity transactions.

During the six months ended December 31, 2003, we issued approximately 17.8 million shares of our common stock upon the exercise of common stock purchase warrants at prices ranging from $0.056 to $0.224 resulting in net proceeds to us of approximately $2.9 million. Subsequent to December 31, 2003 and through February 5, 2004, we have issued approximately 6.6 million shares of our common stock upon the exercise of common stock purchase warrants at prices ranging from $0.10 to $0.224 per share, resulting in net proceeds to us of approximately $876,000.

As of December 31, 2003, there is no principal balance outstanding on our convertible debentures, as the previously outstanding debentures were satisfied either by payment of the outstanding obligation or through the issuance of shares of Viragen common stock upon conversion of the debentures. During the six months ended December 31, 2003, we issued approximately 36.8 million shares of our common stock upon conversion of outstanding convertible debentures and a Note. These shares were issued at prices ranging from $0.056 to $0.3173. As of June 30, 2003, the outstanding principal balance of convertible debentures consisted of the outstanding principal of the June 2003 convertible debentures, the April 2003 convertible debentures, and the August 2002 Note totaling approximately $5.55 million, $1.24 million, and $0.5 million, respectively.

We have experienced losses and a negative cash flow from operations since inception. During the three and six months ended December 31, 2003, we incurred losses of approximately $7,338,000 and $11,241,000, respectively. For the fiscal years ended June 30, 2003, 2002 and 2001 we incurred losses of approximately $17,349,000, $11,089,000, and $11,008,000, respectively. At December 31, 2003 we had an accumulated deficit of approximately $113,533,000. Management anticipates additional future losses as it commercializes its natural human alpha interferon product and conducts additional research activities and clinical trials to obtain additional regulatory approvals. Management believes we have enough cash to support operations through December 31, 2004. However, we will require substantial additional funding to support our operations subsequent to December 31, 2004. Managements plans include obtaining additional capital through equity and debt financings. No assurance can be given that additional capital will be available when required or upon terms acceptable to us.

Our future capital requirements are dependent upon many factors, including: revenue generated from the sale of our natural human alpha interferon product, progress with future and ongoing clinical trials; the costs associated with obtaining regulatory approvals; the costs involved in patent applications; competing technologies and market developments; and our ability to establish collaborative arrangements and effective commercialization activities. For all of fiscal 2004, we anticipate the need of approximately $9.0 to $10.0 million for operating activities, $1.5 million for investing activities and $1.0 million to service our financing obligations.

Table of Contents

Manufacturing of our natural human alpha interferon at our leased facility in Umea, Sweden, has been suspended since March 31, 2003. This planned break in routine manufacturing was necessary to allow for certain steps of the production process to be segregated and transferred to our owned facility, which is also located in Umea, Sweden, which is in the process of being renovated. Renovation of this facility commenced in 2003 and is in line with our plan to expand our productive capacity of our natural human alpha interferon. The estimated total cost of this initial phase is $1.2 million and it is scheduled to be completed during 2004. As of December 31, 2003, we have invested approximately $775,000 on the renovation of this facility and the project is proceeding according to plan. We believe that our current inventory levels are sufficient to meet our current sales forecasts during the period in which routine production is planned to be suspended. We plan to expand the use of our owned facility in phases based on product demand and available financing. Maximum expansion, if warranted, could cost up to an additional $10 million

Table of Contents

Results of Operations

Product sales

For the three months ended December 31, 2003, product sales totaled approximately $60,000 compared to product sales of approximately $127,000 for the quarter ended December 31, 2002. For the six months ended December 31, 2003, product sales totaled approximately $112,000 compared to approximately $472,000 for the six months ended December 31, 2002. The decreases in product sales of approximately $67,000 and $360,000 for the three and six months ended December 31, 2003, respectively, are primarily attributed to the absence of sales to Alfa Wasserman under a contractual arrangement which expired in December 2002. For the three and six months ended December 31, 2002, sales to Alfa Wasserman totaled approximately $56,000 and $378,000, respectively.

During 2002 and 2003, we entered into several agreements for the distribution of our natural human alpha interferon, Multiferon, in various countries. To date, we have not recognized revenue from many of these agreements. The majority of these agreements require that the distributor obtain the necessary regulatory approvals, which are yet to be obtained. Regulatory approval is a mandatory step in the marketing of a drug, but it is by no means the final challenge in marketing a biopharmaceutical product. Multiferon is a critical care product that is typically administered in a hospital setting. Therefore, in certain instances, it must be part of a hospitals approved formulary to enable physicians to be able to prescribe the product. This may include becoming approved within a nationalized network of hospitals. Also, the physicians must be educated as to the potential merits and advantages of the product.

There are other challenges associated with international marketing activities including: language and cultural barriers, poorly organized regulatory infrastructure and/or compliance, performance of assigned distributors, governments willingness to promote cheaper generic products and the general populations inability to afford private care drug products. It may take significant time to overcome these challenges with no assurance that a particular market will ever be effectively penetrated.

Cost of sales

Cost of sales and excess/idle production costs totaled approximately $532,000 and $901,000 for the three and six months ended December 31, 2003, respectively. The increases in cost of sales of approximately $428,000 and $479,000 for the three and six months ended December 31, 2003, respectively, and the resulting negative margins are attributed to excess/idle capacity costs. Excess/idle capacity costs represent fixed production costs incurred at our Swedish manufacturing facility, which were not absorbed as a result of the suspension of routine manufacturing as of March 31, 2003. This planned break in routine manufacturing was necessary to allow for certain steps of our production process to be segregated and transferred to our owned facility also located in Umea, Sweden, which is currently being renovated. We will continue to incur excess/idle production costs until we resume production at normal operating levels that absorb our fixed production costs.

Research and Development Costs

Research and development costs include scientific salaries and support fees, laboratory supplies, consulting fees, contracted research and development, equipment rentals, repairs and maintenance, utilities and research related travel. Research and development costs totaled approximately $811,000 for the three months ended December 31, 2003 compared to approximately $914,000 for the three months ended December 31, 2002. This decrease of approximately $103,000 is mainly attributed to a decrease in costs related to oncology projects of approximately $217,000. This decrease was offset in part by increases in costs related to our avian transgenic project and costs incurred in the development of potential commercial applications of our natural human alpha interferon product totaling approximately $37,000 and $66,000, respectively.

For the six months ended December 31, 2003, research and development costs totaled approximately $1,626,000 compared to approximately $1,747,000 for the three months ended December 31, 2002. This decrease of approximately $121,000 is mainly attributed to a decrease in costs related to oncology projects of approximately $521,000. This decrease was offset in part by increases in costs related to our avian transgenic project and costs incurred in the development of potential commercial applications of our natural human alpha interferon product totaling approximately $193,000 and $147,000, respectively.

We expect our overall research and development costs to decrease as we focus our efforts on containing costs and directing resources to priority programs. We will continue incurring research and development costs for additional clinical trial projects associated with Multiferon as well as other projects to more fully develop potential commercial applications of our natural human alpha interferon product, as well as broaden our potential product lines in the areas of avian transgenics and oncology. Our ability to successfully conclude additional clinical trials, a prerequisite for expanded commercialization of any product, is dependent upon our ability to raise significant additional funding.

Table of Contents

Selling, General and Administrative Expenses

Selling, general and administrative expenses include administrative personnel salaries and related expenses, office and equipment leases, utilities, repairs and maintenance, insurance, legal, accounting, consulting, depreciation and amortization. Selling, general and administrative expenses totaled approximately $1,727,000 for the three months ended December 31, 2003 compared to approximately $1,716,000 for the three months ended December 31, 2002. This increase of approximately $11,000 or 1% is mainly attributed to increases in consulting fees, insurance expense, and a reserve for notes receivable associated with a former director at our Florida headquarters totaling approximately $55,000, $35,000, and $64,000, respectively. These increases were offset by decreases in payroll related expenses and legal fees incurred at our Florida headquarters totaling approximately $184,000 and $41,000, respectively.

For the six months ended December 31, 2003, selling, general and administrative expenses totaled approximately $3,193,000 compared to approximately $3,447,000 for the three months ended December 31, 2002. This decrease of approximately $254,000 is mainly attributed to decreases in payroll related expenses and legal fees at our Florida headquarters totaling approximately $396,000, and $62,000, respectively. These decreases were partially offset by increase in insurance expense and a reserve recorded on notes receivable associated with a former director at our Florida headquarters totaling approximately $70,000 and $64,000, respectively.

We expect our overall selling, general and administrative expenses to decrease in the foreseeable future as a result of cost cutting efforts to reduce overall administrative expenses, which will be partially offset by additional costs related to the commercialization of Multiferon. Our successful commercialization of Multiferon will require additional marketing and promotional activities which is dependent upon our ability to raise significant additional funding.

Amortization of Intangible Assets

Amortization of intangible assets includes the amortization of the purchase price allocated to separately identified intangible assets obtained in the acquisition of ViraNative in September 2001. The separately identified intangible assets consist of developed technology and a customer contract. The developed technology is being amortized over its estimated useful life of approximately 14 years. The customer contract was amortized over the term of the contract, which expired in December 2002. For the three and six months ended December 31, 2003, amortization of intangible assets totaled approximately $39,000 and $76,000, respectively, compared to approximately $58,000 and $115,000 during the three and six months ended December 31, 2002. These decreases of approximately $19,000 and $39,000 in the amortization of intangible assets for the three and six months ended December 31, 2003, are a result of the acquired customer contract being fully amortized as of December 2002.

Interest and Other Income

The primary components of interest and other income are interest earned on cash and cash equivalents, grant income from government agencies in Scotland, sublease income on certain office space in our facility in Scotland, transaction gains or losses on foreign exchange, gains or losses on the disposal of property and equipment, and income generated from research and development support services provided by our Swedish subsidiary. Interest and other income for the three and six months ended December 31, 2003, totaled approximately $253,000 and $476,000, respectively. Interest and other income increased approximately $130,000 and $311,000 when compared to the three and six months ended December 31, 2002, respectively. These increases are mainly attributed to increases in grant income for the three and six months ended December 31, 2003 totaling approximately $90,000 and $183,000, respectively. Also contributing to these increases in interest and other income were increases in income generated from research and development support services provided by our Swedish subsidiary totaling approximately $25,000 and $124,000 for the three and six month ended December 31, 2003

Table of Contents

Interest Expense

Interest expense for the three and six months ended December 31, 2003 totaling approximately $4,895,000 and $6,687,000, respectively, primarily consists of interest expense on our convertible debentures of approximately $4,848,000 and $6,598,000, respectively. Approximately $4,616,000 and $6,279,000 of these amounts represent non-cash interest expense for the three and six months ended December 31, 2003, respectively. This non-cash interest expense is comprised of the amortization of the discounts on the debentures, which arose from detachable warrants and shares of common stock issued with the debentures, as well as the debentures beneficial conversion feature.

Included in interest expense for the three and six months ended December 31, 2003, was an adjustment to record non-cash interest expense totaling approximately $1.4 million as a result of the revaluation of the warrants issued in connection with the April and June 2003 convertible debentures. At the time of issuance the warrants were valued using their expected lives, which was less than their contractual lives. Ernst & Young LLP, our independent auditors, concurred with this approach. In January 2004, we were informed by Ernst & Young LLP that they had revaluated their interpretation of the accounting literature as it relates to the accounting for common stock purchase warrants issued in connection with financing transactions. As a result of this subsequent interpretation, we and Ernst & Young LLP determined that valuing the warrants issued in connection with our April and June 2003 securities purchase agreements using their expected lives was not correct. By using the expected lives of the warrants, less value was attributed to them than if we had used the contractual lives. Thus, an additional discount of approximately $1,423,000 would have been recorded on the convertible debentures issued under the April and June 2003 securities purchase agreements by using the contractual lives on the warrants. This additional discount associated with the convertible debentures resulted in an understatement of our non-cash interest expense of approximately $436,000 in the quarter ended June 30, 2003 and $477,000 in the quarter ended September 30, 2003. After consideration of all of the facts and circumstances, we recognized the full amount of the prior period non-cash interest expense in the quarter ended December 31, 2003, as management believes it is not material to any period affected. Also, we recorded additional non-cash interest expense of approximately $509,000 in the quarter ended December 31, 2003 relating to this matter.

Also included in interest expense is interest incurred on the debt facilities maintained by our Swedish subsidiary totaling approximately $45,000 and $84,000 for the three and six months ended December 31, 2003, respectively, compared to interest expense totaling approximately $49,000 and $99,000 for three and six months ended December 31, 2002. These credit facilities have interest rates ranging from 5.25% to 9.90%.

Income Tax Benefit

We are subject to tax in the United States, Sweden, and the United Kingdom. These jurisdictions have different marginal tax rates. For the six months ended December 31, 2003 and December 31, 2002, income tax benefit totaled approximately $22,000 and $39,000, respectively. Income tax benefit for these periods is primarily related to the amortization expense on certain intangible assets. Due to the treatment of the identifiable intangible assets under Statement of Financial Accounting Standards (SFAS) No. 109, Accounting for Income Taxes, our balance sheet reflects a deferred tax liability of approximately $522,000 as of December 31, 2003, all of which is related to our developed technology intangible asset acquired on September 28, 2001.

Table of Contents

Research and Development Projects

Avian Transgenics

Our avian transgenic project is designed to enable Viragen to produce protein-based drugs, including monoclonal antibodies, inside the egg whites of transgenic developed chickens. Our goal is to develop a technology which will enable us to meet the large-scale production requirements for our own therapeutic protein products. We also believe that this technology will allow us to offer to others in the biopharmaceutical industry an alternate faster method of production of their protein-based products with a higher capacity and at a lower cost.

Avian transgenics offers a potential solution to the production bottleneck currently limiting the growth and contributing to the high cost of protein drugs. Existing protein production technologies are often inefficient and costly. In addition, the anticipated explosion in protein drug approvals together with protein-based drugs in pre-clinical and Phase I or Phase II clinical trials has created a worldwide shortage of production capacity for these protein-based products.

We believe our avian transgenics project will offer a rapid and cost effective way to produce large volumes of therapeutic proteins. In addition to meeting the current and future alternative production demands of the biopharmaceutical industry and generating significant revenue for Viragen, this project could also accelerate the progress of several life-saving drugs to the market at an affordable cost.

For the three and six months ended December 31, 2003, costs incurred related to the avian transgenics project totaled approximately $245,000 and $476,000, respectively. For the fiscal years ended 2003, 2002, and 2001, we incurred costs related to the avian transgenics project totaling approximately $949,000, $778,000 and $477,000, respectively. Since the date of inception of this project, we have incurred approximately $2,680,000 in research and development costs.

We estimate that we may be able to begin commercialization of our avian transgenics technology during calendar year 2004. However, it should be noted that additional work is necessary to be able to express the targeted proteins in the egg whites of transgenic chickens in sufficient quantities to make the process commercially viable. There can be no assurance as to if, or when, this target will be met. Additional costs to be incurred through commercialization are estimated at $1.5 million to $2.5 million. Future material net cash inflows, if any, are not reasonably certain and are not determinable at this time. This is a new technology and there is no precedent to be used to estimate the size of the potential market or the demand for this technology.

Oncology

Our research and development projects in the field of oncology are focused on the development of therapeutic proteins for the treatment of targeted cancers. Our oncological projects are defined as follow:

CD55 Therapy

In collaboration with Cancer Research UK, we are developing a monoclonal antibody designed to block the protective effect of the protein CD55 on the surface of tumor cells. The protein CD55 is one of a number of proteins which protect normal healthy cells from being destroyed by the complement system. The problem arises when cancer cells also express this control protein to camouflage themselves from the immune system at levels up to 100 fold greater than normal. Under a worldwide exclusive commercial license granted to us, we are developing an antibody to remove this protection from tumor cells. A successful therapy could also offer protection against cancer spreading. We believe this technology may prove useful in the treatment of colorectal, breast, ovarian and certain bone cancers.

Table of Contents

For the three and six months ended December 31, 2003, costs incurred related to the CD55 project totaled approximately $67,000 and $88,000, respectively. For the fiscal years ended 2003, 2002, and 2001, we incurred costs related to the CD55 project totaling approximately $144,000, $298,000 and $258,000, respectively. Since the date of inception of this project, we have incurred approximately $788,000 in research and development costs.

The CD55 vaccine project has not reached clinical trials and we do not expect to enter into clinical trials earlier than third calendar quarter of 2004, if at all.


IEP 11

We entered into an agreement with the University of Miamis Sylvester Comprehensive Cancer Center to develop anti-cancer technology. The joint project is designed to develop a novel form of an immune enhancing drug that has shown promise by inhibiting tumor growth in rats for a broad range of cancers. This drug is a novel 11 amino acid peptide called IEP 11, which was derived from a tumor transmembrane glycoprotein. It possesses anti-cancer vaccine properties both prophylactically and therapeutically.

For the three and six months ended December 31, 2003, costs incurred related to the IEP 11 project totaled $5,000. For the fiscal year ended 2003 we incurred costs related to the IEP 11 project totaling approximately $85,000. Since the date of inception of this project, we have incurred approximately $90,000 in research and development costs.

It is too early too determine if and when this project will make it to clinical trials.

R24 Monoclonal Antibody

In collaboration with Memorial Sloan-Kettering Cancer Center, we have initiated research on monoclonal antibodies targeting ganglioside GD3 for the treatment of melanoma and possibly certain other cancers. Monoclonal antibodies are laboratory-produced, highly specialized therapeutic proteins designed to locate and bind to targeted cancer cells.

For the three and six months ended December 31, 2003, costs incurred related to the R24 project totaled approximately $15,000. For the fiscal years ended 2003, 2002, and 2001, we incurred costs related to the R24 project totaling approximately $598,000, $629,000 and $218,000, respectively. Since the date of inception of this project, we have incurred approximately $1,553,000 in research and development costs.

Based on ongoing laboratory results, and our recent cost cutting program, further development of this project has been put on hold pending further review of compiled data.

Notch-1 Monoclonal Antibody

Under a worldwide exclusive license from the U.S. National Institutes of Health (NIH), we were researching the clinical applications of a monoclonal antibody that recognizes the Notch-1 protein. Binding of the antibody to the protein signals the immune response to activate lymphocytes, modulating immunity. The antibody may also be useful in adjuvant therapies. During fiscal 2003, we suspended research and related expenditures on this project to explore scientific issues related to the license from the NIH. Subsequent to our fiscal year end, we terminated the license.

Table of Contents

For the three and six months ended December 31, 2003, costs incurred related to the Notch-1 project totaled approximately $7,000. For the fiscal years ended 2003, 2002, and 2001, we incurred costs related to the Notch-1 project totaling approximately $2,000, $586,000 and $497,000, respectively. Since the date of inception of this project, we have incurred approximately $1,092,000 in research and development costs.

Estimated completion dates, completion costs, and future material net cash inflows, if any, for the above oncological projects are not reasonably certain and are not determinable at this time. The timelines and associated costs for the completion of biopharmaceutical research and product development programs are difficult to accurately predict for various reasons, including the inherent exploratory nature of the work. The achievement of project milestones is dependent on issues which may impact development timelines and can be unpredictable and beyond our control. These issues include; availability of capital funding, presence of competing technologies, unexpected experimental results which may cause the direction of research to change, accumulated knowledge about the intrinsic properties of the candidate product, the availability of contract cell banking and manufacturing slots for the preparation of Good Manufacturing Practices grade material, results from preclinical and clinical studies, potential changes in prescribing practice and patient profiles and regulatory requirements.

The completion of all of the above research and development projects is dependent upon our ability to raise significant additional funding or our ability to identify potential collaborative partners that would share in project costs. Our future capital requirements are dependent upon many factors, including: revenue generated from the sale of our natural human alpha interferon product, progress with future clinical trials; the costs associated with obtaining regulatory approvals; the costs involved in patent applications; competing technologies and market developments; and our ability to establish collaborative arrangements and effective commercialization activities.

Recent Accounting Pronouncements

In January 2003, FASB issued Interpretation Number 46, Consolidation of Variable Interest Entities (FIN No. 46). This interpretation of Accounting Research Bulletin No. 51, Consolidated Financial Statements, provides guidance for identifying a controlling interest in a variable interest entity established by means other than voting interests. FIN No. 46 also requires consolidation of a variable interest entity by an enterprise that holds such a controlling interest. In December 2003, the FASB completed its deliberations regarding the proposed modification to FIN No. 46 and issued Interpretation Number 46R, Consolidation of Variable Interest Entities an Interpretation of ARB No. 51 (FIN No. 46R). The decisions reached included a deferral of the effective date and provisions for additional scope exceptions for certain types of variable interests. Application of FIN No. 46R is required in financial statements of public entities that have interests in variable interest entities or potential variable interest entities commonly referred to as special-purpose entities for periods ending after December 15, 2003. Application by public entities (other than small business issuers) for all other types of entities is required in financial statements for periods ending after March 15, 2004. We do not expect the adoption of FIN No. 46R to have a material impact on our consolidated financial position, results of operations or cash flows.

In April 2003, the FASB issued SFAS No. 149, Amendment of Statement 133 on Derivative Instruments and Hedging Activities. SFAS 149 improves financial reporting by requiring that contracts with comparable characteristics be accounted for similarly. SFAS 149 clarifies 1) the circumstances in which a contract with an initial net investment meets the characteristics of a derivative, 2) when a derivative contains a financing component and amends certain other existing pronouncements. This Statement is effective for contracts entered into or modified after June 30, 2003. Adoption of this standard did not have a material impact on our consolidated financial position, results of operations or cash flows.

Table of Contents

In May 2003, the FASB issued SFAS No. 150, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity. SFAS No. 150 requires that certain financial instruments, which under previous guidance were accounted for as equity, be accounted for as liabilities. The financial instruments affected include mandatorily redeemable stock, certain financial instruments that require or may require the issuer to buy back some of its shares in exchange for cash or other assets and certain obligations that can be settled with shares of stock. SFAS No. 150 is effective for all financial instruments entered into or modified after May 31, 2003 and must be applied to existing financial instruments effective after the beginning of the first fiscal period after June 15, 2003. Adoption of this standard did not have a material impact on our consolidated financial position, results of operations or cash flows.

Table of Contents



(c) 1995-2004 Cybernet Data Systems, Inc. All Rights Reserved


Received by Edgar Online Feb 10, 2004


CIK Code: 0000353482
Accession Number: 0000950144-04-001016

-0-
Income Statement Get Income Statement for:




View: Quarterly Data | Annual Data All numbers in thousands
PERIOD ENDING 31-Dec-03 30-Sep-03 30-Jun-03 31-Mar-03
Total Revenue 60 52 111 48
Cost of Revenue 532 369 540 324

Gross Profit (472) (317) (429) (276)

Operating Expenses
Research Development 811 814 665 855
Selling General and Administrative 1,727 1,466 1,854 1,920
Non Recurring - - - -
Others 39 37 35 34

Total Operating Expenses - - - -


Operating Income or Loss (3,049) (2,635) (2,982) (3,085)

Income from Continuing Operations
Total Other Income/Expenses Net 253 223 123 174
Earnings Before Interest And Taxes (2,796) (2,412) (2,859) (2,911)
Interest Expense 4,895 1,792 3,745 1,508
Income Before Tax (7,692) (4,204) (6,604) (4,419)
Income Tax Expense (11) (11) (11) (11)
Minority Interest 343 290 424 376

Net Income From Continuing Ops (7,338) (3,903) (6,169) (4,032)

Non-recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Changes - - - -
Other Items - - - -


Net Income (7,338) (3,903) (6,169) (4,032)
Preferred Stock And Other Adjustments (1) (1) (1) (1)

Net Income Applicable To Common Shares ($7,338) ($3,904) ($6,170) ($4,033)
Viragen Launches Multiferon Sales And Marketing Program In Mexico

PLANTATION, Fla., Feb. 18 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Company has initiated its Multiferon(TM) marketing and sales program in Mexico with the natural human alpha interferon drug being shipped to its distributor, Laboratorios Pisa. As part of the product`s launch, a presentation was made on February 14th at the Mexican National Oncology Congress in Veracruz that discussed the merits of Multiferon as an adjuvant treatment for malignant melanoma, a potentially lethal skin cancer.

"Our Multiferon Marketing Team has been working closely with our strategic partner, Laboratorios Pisa, to commence with our marketing and sales program in Mexico and we are pleased to report that we have shipped an initial order," stated Viragen`s Executive Vice President, Mel Rothberg. "As part of this campaign, Laboratorios Pisa sponsored a Multiferon presentation at an important Mexican National Oncology Congress sponsored by the National Cancer Institute (INCAN) that discussed the drug`s potential to treat malignant melanoma. Moving forward, we will target the treatment of a variety of viral and malignant diseases including hepatitis B, hepatitis C and certain cancers."

At a plenary session of the Mexican National Oncology Congress, Professor Orjan Strannegard from Goteborg University in Sweden made a presentation titled, "Adjuvant Treatment of Malignant Melanoma with Natural Interferon Alpha." Dr. Strannegard serves as a Director for ViraNative AB, Viragen`s Swedish interferon manufacturing subsidiary.

Dr. Strannegard made the following conclusions supporting the use of Multiferon as an adjuvant treatment for malignant melanoma:

* Multiferon has antiviral, antiproliferative and immunological properties that are different from, and in some cases, superior to those of recombinant alpha interferons.

* In high-risk melanoma, adjuvant treatment with dacarbazine followed by low-dose natural alpha interferon results in a highly significant beneficial effect on relapse-free survival.

* Preliminary results indicate that the increase in relapse-free survival is followed by a substantial increase in overall survival in patients given dacarbazine and natural alpha interferon.

* The survival advantage of dacarbazine and natural alpha interferon appears to surpass that of adjuvant treatment with high or medium doses of recombinant alpha interferon.

* Partly because of the low doses used, natural alpha interferon is very well tolerated by patients.

* Sequential biochemotherapy involving natural alpha interferon may be preferable to regimes where the drugs are given simultaneously to the patients.

Dr. Strannegard`s conclusions were based upon a series of studies evaluating the use of various interferons for the treatment of malignant melanoma, including a controlled Phase II/III clinical study for the adjuvant treatment of malignant melanoma with Multiferon. The results from this original 156 patient study, conducted at 20 sites in Germany, were presented at a national German oncology conference in 2003.

Dr. Jorge Yoma, Medical Director for Laboratorios Pisa, commented, "Our feedback from the Congress was very encouraging. We believe that Multiferon is the first natural human alpha interferon that can be priced competitively with recombinant versions, so we are making a very strong case supporting its use to physicians and patients seeking an alternative interferon therapy."

In other news, Viragen announced that it will hold its Annual Meeting of Stockholders at the Renaissance Plantation Hotel located at 1230 Pine Island Road, Plantation, Florida, on Friday, March 12, 2004 at 2:00 P.M. (EST).

About Alpha Interferon:

The majority of alpha interferons that are marketed are single-subtype recombinant interferons. Therapy resistance is not unusual with recombinant interferons with a significant percentage of patients failing to respond to standard therapy. In some instances, recombinant interferon is rejected by the patient`s immune system, usually caused by the formation of neutralizing antibodies which may lead to a loss of clinical efficacy. Also, many patients cannot tolerate the adverse side effects sometimes associated with recombinant therapy. High doses of recombinant interferon may cause serious, even life- threatening side effects.

About Multiferon(TM):

Multiferon is a highly purified, multi-subtype, natural human alpha interferon derived from human white blood cells and is approved in Sweden and Mexico for the second-line treatment of any and all diseases in which patients show an initial response to recombinant (synthetic) alpha interferon followed by treatment failure, probably due to the formation of neutralizing antibodies.

Viragen`s natural interferon is also approved for sale in the following countries as a second-line therapy for the treatment of Hairy Cell Leukemia (HCL) and Chronic Myelogenous Leukemia (CML): Czech Republic, Egypt, Hong Kong, Indonesia, Myanmar, South Africa and Thailand. Work is ongoing to expand the approved indications in these countries. Regulatory approval processes are also underway in a number of other South American, Middle East and Far East territories.

Fraktal
@ Frakt@l

den Text habe ich auch gelesen. Aber das Übersetzungsprogramm kann man vergessen und mein Englisch ist nicht so gut.

Kannst du mit dem Text was anfangen??

Gruß bella
bleibt die Frage wer verkauft laufend, obwohl die Zukunftsaussichten doch so " toll " sind ?

wenn sie Ende nächster Woche nicht über 27 US cent stehen, fliegen sie aus meinem Depot

VIRAGEN
865 S.W. 78th Avenue, Suite 100
Plantation, Florida 33324

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To be held on March 12, 2004


To the Stockholders of Viragen, Inc.

PLEASE TAKE NOTICE that Viragen, Inc., a Delaware corporation, will hold its 2003 annual meeting of stockholders at the Renaissance Plantation Hotel located at 1230 Pine Island Road, Plantation, Florida, on Friday, March 12, 2004 at 2:00 P.M., local time, or at any and all adjournments for the following purposes:

1. To elect four directors to the board of directors, one who will be classified as a class B director and three who will be classified as class C directors, to serve for the term of their designated class and until their successors have been elected and qualified;


2. To authorize the possible issuance of more than 19.9% of our common stock in a June 2003 financing transaction in which Viragen received gross proceeds of $5,554,122 through the sale of its convertible debentures and common stock purchase warrants to five institutional investors;


3. To authorize the issuance of more than 19.9% of our common stock in a September 2003 financing transaction in which Viragen received gross proceeds of $4,775,000 through the sale of its common stock and common stock purchase warrants to eight institutional investors;


4. To authorize the issuance of more than 19.9% of our common stock in a December 2003 financing transaction in which Viragen received gross proceeds of $4,550,000 through the sale of its common stock and common stock purchase warrants to six institutional investors;


5. To ratify the appointment of Ernst & Young LLP, as our independent auditors; and


6. To transact other business that may properly come before the meeting or any adjournment.


A copy of our proxy statement, which is being first mailed to stockholders on or about February 12, 2004, is attached.

The board of directors has fixed the close of business on January 30, 2004, as the record date for the determination of stockholders entitled to notice of, and to vote at, the meeting. Viragen’s financial statements for the fiscal year ended June 30, 2003 are contained in the accompanying annual report on Form 10-K. Viragen’s financial statements for the quarterly period ended December 31, 2003 are contained in the accompanying quarterly report on Form 10-Q. Neither the annual report nor the quarterly report form any part of the material for the solicitation of proxies. If you do not expect to be present at the meeting, you are urged to complete, date, sign and return the enclosed proxy. No postage is required if the enclosed envelope is used and mailed in the United States. You may also vote electronically via the internet or by telephone.


By Order of the Board of Directors,

/s/ Dennis W. Healey

--------------------------------------------------------------------------------

Dennis W. Healey, Secretary

Plantation, Florida
February 9, 2004

Fraktal
Viragen and Roslin Institute Announce Extended Agreement

Project Aims to Produce Biotech Drugs Faster and Cheaper in the Eggs of Transgenic Hens

PLANTATION, Fla., March 8 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Company has extended its agreement with Scotland`s Roslin Institute to develop Avian Transgenic Technology. The agreement, extended by two years, continues to provide Viragen with the worldwide exclusive rights to commercialize avian transgenic biomanufacturing technology, believed to be capable of producing therapeutic protein-based drugs on a large scale with advantages that include lower costs, increased efficiency and quality of product.

"We are pleased to continue this important partnership with Scotland`s Roslin Institute," stated Viragen`s President and CEO, Mr. Robert C. Salisbury. "This is a high-priority project and we are encouraged by research results that suggest that Project Leader, Dr. Helen Sang, and the research teams at the Roslin Institute and Viragen Scotland are on a pathway to achieve the necessary scientific milestones that could establish Viragen and Roslin as leaders in this field."

Roslin Institute`s Deputy Director, Dr. Harry Griffin, applauded the aim of the project. "The potential merits of this technology are many, but the patient would be the ultimate beneficiary. These specially developed transgenic hens should be able to produce many kinds of protein drugs in their eggs which could be used to fight a wide range of diseases. Working with Viragen, we look forward to developing an effective manufacturing platform designed to provide patients with faster access to new drugs."

About Avian Transgenic Technology

Viragen holds the worldwide exclusive license to commercialize Avian Transgenic Technology as granted by Roslin Institute. This project is designed to substitute chicken eggs for expensive bioreactor vessels presently used in the manufacture of protein-based drugs. Upon the successful completion of this project, flocks of specially produced transgenic chickens would lay virtually unlimited numbers of eggs which would have significant amounts of the target drug in the egg whites. The proportion of protein drugs, including monoclonal antibodies, under development is forecast to be expanding rapidly and manufacturing constraints, including lack of adequate facilities, have been recognized.


Fraktal
Viragen hat einen neuen Vorstandsvorsitzenden (CEO). Hier hat man sich wohl einen Profi für Umsatz- und Gewinnwachstum hereingeholt. Klingt nicht schlecht ...

VIRAGEN NAMES NEW PRESIDENT AND CEO
Growth of Multiferon™ Sales Program Named as Top Priority

PLANTATION, FLORIDA – March 11, 2004 – Viragen, Inc. (AMEX: “VRA”) today announced the appointment of Charles A. Rice as President and Chief Executive Officer. He replaces Robert C. Salisbury who will continue to serve as a member of Viragen’s Board of Directors and as President and CEO of Viragen’s wholly-owned avian transgenics subsidiary, ViraGenics, Inc.

Mr. Rice is a proven executive with 30 years of experience managing, directing and building stockholder value for companies in the life science industry. Most recently, he served as Group President of KV Pharmaceutical Company (NYSE: “KVa/KVb”) with responsibility for commercial activities. He previously served as President and CEO of Dey, Inc., a division of Germany’s Merck KGaA, where he developed and implemented strategies to create a rapidly growing and profitable business. He was credited for growing Dey’s sales 15-fold over a 10 year period and expanding its workforce to over 1,000 people. Under Mr. Rice’s leadership, Merck KGaA recognized Dey as one of its most profitable units.

“With the addition of Charles Rice, we gain a skilled and seasoned executive determined to steer Viragen with focus and innovative vision which we expect will translate into realizing commercial opportunities,” stated Viragen’s Chairman, Carl N. Singer. “Charles has an outstanding track record of creating aggressive strategies while increasing stockholder value for rapidly growing organizations and his leadership should greatly contribute to drive the Company’s global initiatives and produce strong business results.”

Commenting on his new role, Mr. Rice stated, “This is an opportunity to work with a solid core of talent and technology and to harness past achievements to take Viragen to the next level – as a leading manufacturer of human natural alpha interferon and respected developer of important new healthcare technologies. ”

“While our top priority will be to improve sales of Multiferon, I am encouraged by Viragen’s pipeline of development products, plus the dramatic potential of Avian Transgenic Technology. I’m excited to join the Viragen team and I look forward to contributing to success for our stockholders as we move forward with our business plan.”

Mr. Rice has a degree in Biology from Georgia College and extensive business education and experience through training and coursework at a variety of domestic and international universities, in addition to continuous participation in industry organizations.

Mr. Singer added, “The Board thanks Robert Salisbury for his service as President and CEO and we look forward to his continued contributions on the VRA Board and steering ViraGenics. Bob accepted senior responsibility during a challenging period and under his direction we have accomplished many important goals. By building upon this foundation, we foresee a period of dynamic growth ahead.”

Fraktal
Hohes Umsatzvolumen heute, aber nur leichter Kursanstieg auf 0,22 US$ (+0,01 US$):

Viragen Announces New Partnerships to Develop Electroporation Technology for Avian Transgenic Biomanufacturing

PLANTATION, Fla., March 30 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Company has entered into an agreement with privately-held RMR Technologies, LLC in Coral Gables, Florida and the University of South Florida (Tampa) to obtain rights to a gene delivery technology to be evaluated in its collaboration with Roslin Institute to develop avian transgenic technology as an efficient and cost-effective biomanufacturing platform for the production of human therapeutic protein drugs. Financial terms were not disclosed.

The agreement provides Viragen with an option to acquire an exclusive worldwide commercial license to this advanced electroporation technology for use within the field of avian transgenics. The gene delivery system, based on a highly developed electrode device, uses a specific combination of pulsed electric fields to introduce a gene sequence into the chick embryo. The goal is to introduce a gene encoding a therapeutic protein into the chicken and thus enable the breeding of generations of chickens that also express this gene. The project aims to breed flocks of transgenic chickens capable of producing high volumes of protein-based drugs, such as cancer-fighting monoclonal antibodies, which would be expressed in the whites of their eggs. The technology is fully protected by a portfolio of patents and patent applications.

Viragen`s Director of Research (Emeritus), Professor William H. Stimson discussed the RMR collaboration at Biotech 2004, an industry event hosted by Florida International University on March 25th. According to Dr. Stimson, "Electroporation is one of three different gene delivery systems we are examining so that we may hold a portfolio of techniques that could be capable of delivering a range of gene constructs designed to express therapeutic proteins in the egg white of hens. Initial feasibility studies were conducted at the University of South Florida and the work is being transferred to Roslin for further evaluation."

"Electroporation" is a term that describes the use of pulsed electric fields to temporarily open microscopic pores in membranes which allow molecules to pass from one side of the cell membrane to the other. When the pulses are properly sequenced, microscopic pores reseal spontaneously and the treated cells continue to grow and function modified by the materials that have been introduced into the cells.

RMR`s Chief Scientific Officer, Dr. Richard Heller, stated, "The electroporation technology developed at RMR differs significantly from `standard` electroporation techniques in the configuration of the electrode and the resulting electrical pulse patterns. Therefore, RMR and Viragen have jointly filed a U.S. patent application covering its use in avian transgenics. It`s a novel and promising application for our technology."

"We are excited by the prospect of our technology being utilized as part of such an ambitious project to offer a preferable method for biomanufacturing," stated Mr. Howard Goldman, President of RMR. "Making drugs in chicken eggs should offer many advantages to traditional production systems and we will work closely with Viragen, Roslin and the University of South Florida to move this vision forward."

For more information, please visit our Web site at: http://www.Viragen.com

About Avian Transgenic Technology:

Viragen holds the worldwide exclusive license to commercialize Avian Transgenic Technology as granted by Roslin Institute (Scotland). The project is designed to develop the common chicken into a pharmaceutical bioreactor, one that can meet the growing need for protein-based human therapeutics. Based on the creation of lines of transgenic hens which have been engineered to produce the target protein in their eggs, this technology is being developed as a cost-effective and efficient alternative to standard biomanufacturing techniques, having many apparent advantages in ease of scale- up, lower costs of production and quality of product produced. The proportion of protein drugs, including monoclonal antibodies, under development is forecast to be expanding rapidly and manufacturing constraints, including lack of adequate facilities, have been recognized.

About RMR Technologies:

RMR specializes in the development of energy field enhanced molecular delivery solutions for biotechnology products and is the collective effort of three University of South Florida scientists, Dr.`s Richard Heller, Richard Gilbert and Mark Jarosezski. RMR scientists have a proven record for creating intellectual property and receiving prestigious grants to maximize their research efforts in the development of cutting-edge electroporation technology. Collectively, they have 35 issued and pending patents.

Fraktal
Die Meldung von heute hat nicht gerade Begeisterung ausgelöst. Der Kurs liegt aktuell bei 0,18 US$ (-18%) bei sehr hohen Umsätzen.

Viragen Announces $20 Million Financing Agreement

PLANTATION, Fla., April 5 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that it has entered into purchase agreements for the issuance and sale of $20 million in convertible promissory notes and common stock purchase warrants. The notes, which will be convertible at market price upon their issuance, were placed with a group of new and returning institutional investors. The $20 million purchase price for the notes and warrants has been placed in escrow pending satisfaction of all conditions precedent to closing, including receipt of stockholder approval for the sale of the notes and warrants, as well as for a reverse split of Viragen`s common stock. The proceeds will be used to progress the research, development, and commercialization of Viragen`s portfolio of healthcare products and technologies, including an allocation to fund clinical studies for the purpose of seeking FDA approval for Multiferon(TM), its natural human alpha interferon which is currently approved for sale in certain international markets.

The Board of Directors has authorized the Company to call a Special Meeting of Stockholders in order to solicit the required stockholder approvals. The reverse stock split, which is expected to be at the rate of 1:10, would affect all shares of common stock outstanding, including those underlying stock options and warrants, immediately prior to the effective time of the reverse split. Viragen intends to disseminate a proxy statement for use in connection with the Special Meeting of Stockholders following receipt of regulatory clearance to do so. Closing of the sale of notes and warrants, at which the notes and warrants will be issued and the purchase price delivered to Viragen, is expected to take place shortly after stockholder approval is obtained.

"This significant investment in Viragen would provide us with the financial flexibility and strength necessary to support organizational growth as we move forward with our mission to build stockholder value," stated Viragen`s Chairman, Mr. Carl N. Singer. "With this opportunity to add stability to our balance sheet, we are recommending a reverse stock split because we believe our stockholders would benefit from an improved capital structure that should appeal to institutional fund managers, research analysts and the professional investment community in general. With longer-term secured funding, a capital restructuring and the advent of expected commercial and scientific milestone achievements, we believe that the Company will be better positioned to create stockholder value." After placement agent fees and expenses, the Company expects to receive approximately $19 million in net proceeds.

Viragen`s President and CEO, Mr. Charles A. Rice, added, "It is our immediate priority to enhance and broaden our international marketing activities in order to increase sales of Multiferon as we develop a strategy that targets its introduction into the United States. This funding would allow us to move forward with these initiatives, as well as support our important research projects."

The purchase agreements provide that Viragen pay interest on the escrowed purchase price at the rate of 10% per annum until the date the stockholders approve the sale of the notes and the reverse stock split, at which time, the interest rate on the escrowed funds will be reduced to 7% per annum. The notes will be convertible into shares of Viragen common stock at market price, subject to adjustment depending upon the market price of Viragen common stock following the reverse split. Warrant coverage will be provided at 120% of the conversion price of the notes. The complete terms of the financing will be detailed in a Current Report on Form 8-K to be filed with the SEC.

"With the proceeds of this transaction added to our current cash balance, we will have approximately $27 million in working capital on hand," reported Viragen`s Chief Financial Officer, Mr. Dennis W. Healey. "It is gratifying that we were able to obtain significant financing under such favorable terms including the notes being convertible at market and the warrants having a strike price above market. We believe that based on the positive developments of the Company and our growth prospects, we have been able to structure a transaction that is mutually beneficial to the Company and our investors."

Fraktal
Scotland Awards Grant to Viragen for Cancer Research

PLANTATION, Fla., April 15 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) and Viragen International, Inc.(NASDAQ-OTCBB:VGNI) (OTC Bulletin Board: VGNI) today announced that Viragen (Scotland) Ltd. has been awarded a prestigious Grant from the Scottish government for the approximate sum of 466,000 pounds sterling ($833,000) for the purpose of supporting the research and development of its anti-CD55 Antibody, a monoclonal antibody designed for the treatment of a broad range of cancers, either alone or in combination with other anti- cancer antibodies.

"The Scottish Executive awarded Viragen`s CD55 Project the maximum dollar amount eligible to be granted by its `SPUR Plus` program," stated Dr. Karen Jervis, Viragen`s Director of Technology and Projects Coordinator. "These grants are designed to reward Scotland`s most promising and innovative research programs, and we are very pleased to be recognized with this funding. We believe the anti-CD55 Antibody represents a novel and powerful approach to cancer therapy by deactivating the tumor`s defense mechanism, thus allowing other anti-cancer antibodies to work better, or itself stimulating the immune system to target and kill cancer cells."

Anti-CD55 Antibody Project:

In collaboration with Cancer Research UK and the University of Nottingham (England), Viragen is developing a monoclonal antibody designed to block the protective effect of the protein CD55 on the surface of tumor cells. The protein CD55 is one of a number of proteins which protect normal healthy cells from being destroyed by the complement system, part of the human immune response against disease. The problem arises when cancer cells also express this control protein to camouflage and protect themselves from the immune system.

The anti-CD55 antibody is designed to remove the tumor`s protective mechanism and, in theory, may boost patient response rates either as a stand- alone therapy or in combination with other antibodies. Viragen holds an option from Cancer Research Technology Limited to acquire an exclusive worldwide license to this platform technology with potential applications in a large number of cancer types.

About Cancer Research Technology Limited:

Cancer Research Technology Limited (CRT) is a specialist technology transfer and development company which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies.

Fraktal
@Frakt

Einsamer Kämpfer


Viragen ist ja fast wieder auf ein Kursniveau, wo sich das Nachdenken lohnt....
Ja, stimmt. Kein Interesse mehr da. Vielleicht aus gutem Grund, denn Ankündigungen von reverse splits und derart massiven Aktienausgaben sind nicht beliebt. Das ist häufig der Startpunkt für weitere Verluste. Wenn Viragen nicht bald mal einen Erfolg meldet ist dem Kurs wohl nicht mehr zu helfen.

Hier eine Meldung von heute:

Viragen Added to PCE Florida Stock Index

PLANTATION, Fla., April 28 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Company has been added as a member of the PCE Florida Index(TM), a market value index consisting of 199 Florida- headquartered public companies with individual market values of less than $250 million.

Developed with the assistance of the Roy E. Crummer Graduate School of Business at Rollins College in Winter Park, Florida, the PCE Florida Index was created to cover emerging Florida-based public companies. Viragen`s stockholders can track the Company`s performance daily in relationship to the index and Florida health care sector at: http://www.pceindexes.com .

Fraktal
Viragen and University of Miami to Advance Anti-Cancer Study

PLANTATION, Fla., May 12 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Company extended its agreement with the University of Miami and UM/Sylvester Comprehensive Cancer Center to develop a novel form of an immune-enhancing drug (IEP 11) that has shown promise in animal studies by inhibiting tumor growth in a broad range of cancers. The agreement continues to provide Viragen with an option to acquire an exclusive worldwide license to commercialize the technology.

"This small peptide molecule called `IEP 11` holds the potential of being a platform technology for the treatment of a broad range of cancers," stated Dr. William H. Stimson, Viragen`s Director of Research (Emeritus). "Initial studies in animals have shown the peptide elicits a powerful immune response against various types of cancer cells. Additionally, those animals that were `IEP 11 immunized` were found to form much smaller tumors or not at all. Our results to date are highly promising and further pre-clinical research studies will be carried out to confirm our preliminary data."

Over the next year, Viragen and their University of Miami collaborators plan to carry out a series of pre-clinical studies designed to demonstrate therapeutic efficacy. IEP 11 has already shown to be able to protect against tumor formation in non-human evaluations, so if it also proves efficacious in treatment regimes, the project is expected to move forward toward human clinical evaluations.

UM/Sylvester was founded in 1992 to provide comprehensive cancer services and today serves as the hub for cancer-related research, diagnosis and treatment at the University of Miami School of Medicine. UM/Sylvester handles more than 1,100 inpatient admissions annually, performs 2,800 surgical procedures and treats 2,900 new cancer patients. All UM/Sylvester physicians are on the faculty of the University of Miami School of Medicine, South Florida`s only academic medical center. In addition, UM/Sylvester physicians and scientists are engaged in more than 150 clinical trials and receive more than $30 million annually in research grants. UM/Sylvester at Deerfield Beach recently opened to better meet the needs of residents of Broward and Palm Beach Counties. This 10,000 square-foot facility at I-95 and S.W. 10th Street offers appointments with physicians from six cancer specialties, complementary therapies from the Courtelis Center, and education and outreach events. http://www.sylvester.org

Fraktal
Viragen bemüht sich redlich, Meldungen zu plazieren, aber dem Kurs hilft es nicht: 0,15 US$

Shelf-Life for Multiferon Extended as Viragen Advances Marketing Campaign

PLANTATION, Fla., May 13 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Swedish Medical Products Agency (MPA) has approved extending the shelf-life of Multiferon(TM) to 18 months from its previously approved labeling of 12 months. Additionally, the Company reports that it has initiated a new sales and marketing campaign for Multiferon in Sweden. The campaign promotes the theme "Multiferon -- the natural choice," highlighting its natural source (human leukocytes), its competitive attributes and its approved uses in Sweden.

"It is our priority objective to increase sales of Multiferon around the world," stated Viragen`s President and CEO, Mr. Charles A. Rice. "The prolonged shelf-life provides us with increased flexibility in production and distribution, and we are working to implement this new labeling in our existing and pending markets. Through our own sales staff in Sweden, our growing network of international distributors and our evolving strategy for the future of the product, we expect Multiferon to become recognized as a leading brand of natural alpha interferon."

The print advertising campaign will debut in a series of Scandinavian and Swedish medical publications, including Acta Oncologica, a leading journal in clinical oncology and the official journal of the five Nordic oncological societies.

For a preview of the Multiferon advertising campaign, please visit: http://www.Viragen.com/multiferonad.htm .

Fraktal
Investors to Hear Directly From Companies Including Sanofi-Synthelabo, Crucell N.V., and BioSante Pharmaceuticals at Biotechnology & Pharmaceuticals Stocks Forum in NY on June 23

Harvard Bioscience, Acambis, and Viragen also to present with Lynn
Sutherland, President of Sutherland Consulting and Bill Alpert,
Senior Editor & Biotechnology Writer for Barron`s, Delivering Keynotes

RICHMOND, Va., May 13 /PRNewswire-FirstCall/ -- Investors interested in Biotechnology and Pharmaceutical stocks will receive the latest updates at the Informed Investors Forum on June 23. This live forum will include presentations by executives from Sanofi-Sythelabo, Crucell N.V.(NASDAQ-NMS:CRXL) , BioSante Pharmaceuticals Inc., Harvard Bioscience Inc.(NASDAQ-NMS:HBIO) , Viragen Inc. and Acambis plc(NASDAQ-NMS:ACAM) . Lynn Sutherland, President of Sutherland Consulting and Bill Alpert, Senior Editor & Biotechnology Writer for Barron`s, will deliver keynote addresses.

The analyst-style forum, which includes presentations from top executives of the firms, followed by question and answer sessions, will be held at The Princeton Club of NY at 15 West 43rd Street starting at 8:30 am. A webcast of the forum will be archived on www.informedinvestors.com following the close of the event.

Sanofi-Synthelabo(NYSE:SNY) (NYSE: SNY) is an international pharmaceutical group engaged in the research, development, manufacture and marketing of pharmaceutical products.

Crucell N.V.(NASDAQ-NMS:CRXL) (Nasdaq: CRXL) is a biotechnology company focused on developing products that prevent and treat infectious diseases.

BioSante Pharmaceuticals Inc. (Amex: BPA) is an emerging pharmaceutical company developing a pipeline of hormone therapy products.

Harvard Bioscience Inc.(NASDAQ-NMS:HBIO) (Nasdaq: HBIO) is a global developer, manufacturer and marketer of a range of specialized products, primarily scientific instruments, used to accelerate drug discovery research.

Acambis plc(NASDAQ-NMS:ACAM) (Nasdaq: ACAM) is a leading developer of vaccines to prevent and treat infectious diseases. Its investigational smallpox vaccine is being developed for governments around the world who are looking to protect their citizens in the event of a smallpox outbreak.

Viragen Inc. (Amex: VRA) is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases.

Informed Investors Forums are the leading online and offline industry- specific investment conferences for investors and a member of the PrecisionIR suite of investor relations services from WILink. To register to attend the Forum, please visit http://www.informedinvestors.com/CustomEvent/85117/index.asp… Companies wanting to participate in the forum should contact Cary Loeser at cloeser@wilink.com.

Fraktal
Heute mal eine schöne Gegenreaktion im Kurs: +15% auf 0,15 US$ bei hohem Volumen.

Stock Market Ratings by StockPickReport.com for JDS Uniphase, Research In Motion Ltd, Charter Communications, Viragen Inc, Honeywell International

SHREVEPORT, La.--(BUSINESS WIRE)--May 18,
2004--StockPickReport.Com (IARD#119079)
http://www.stockpickreport.com/bw.php makes these short-term stock
recommendations:

JDS Uniphase (NASDAQ:JDSU) - WEAK SELL
http://www.stockpickreport.com/ratingbw.php?sym=JDSUResearch In Motion Ltd(NASDAQ-NMS:RIMM)
(NASDAQ:RIMM) - BUY
http://www.stockpickreport.com/ratingbw.php?sym=RIMM

Charter Communications (NASDAQ:CHTR) - WEAK SELL
http://www.stockpickreport.com/ratingbw.php?sym=CHTRViragen Inc (AMEX:VRA) - STRONG BUY
http://www.stockpickreport.com/ratingbw.php?sym=VRAHoneywell International Inc(NYSE:HON)
(NYSE:HON) - WEAK SELL
http://www.stockpickreport.com/ratingbw.php?sym=HON


Fraktal
Viragen`s CEO, Charles A. Rice, Outlines Growth Strategy to Stockholders

PLANTATION, Fla., May 25 /PRNewswire-FirstCall/ -- The following is a letter from the President and CEO of Viragen, Inc. (Amex: VRA). In addition to these comments, stockholders and potential investors are referred to the Company`s SEC filings, including Form 10-K and Form 10-Q (Annual and Quarterly Reports); press releases; Website; and other publicly disseminated information which is available upon request by contacting the Company.

Dear Stockholder,

Nearing the completion of my first 60 days as President and CEO, I would like to report to you on some progress we are making at Viragen.

I believe there is an existing foundation here that is ripe to create immediate and long-term value for our stockholders. While there are significant challenges which need to be navigated to be successful, we are making changes now that will direct us toward that success. I am establishing a renewed focus to maximize the value of our assets for our stockholders.

Because some of our growth strategies are in the process of being negotiated, I cannot discuss all of my plans in this letter. However, I would like to update you on certain activities, including some new initiatives designed to enhance and complement those which have been ongoing and progressing. There are two things that we must do, these being: 1) increase revenues and 2) continue to control expenses.

Multiferon(TM)
Manufacturing -- We have previously announced the ongoing process of modernizing our production capabilities for the manufacturing of Multiferon(TM) in Sweden. I am pleased to report that we are on schedule to complete the validation of the new construction and subsequent inspection by Swedish authorities before the end of this year. I would like to congratulate our team for their excellent work on this important project.

I would also like to stress the importance of state-of-the-art and fully compliant manufacturing facilities, equipment and processes for the production of Multiferon. We can be very proud of our Ersboda and Umea sites. Continuous improvement in our manufacturing systems is one of the best possible uses of our capital.

Marketing -- There is no better short-term means to build value in Viragen than to increase the sales of Multiferon. This is a great product but it has been under the radar screen of high prescribers in territories where it is approved. It requires new marketing initiatives to meet our expectations. I am pleased to report that we have put into effect several changes in order to achieve our new objective of making Multiferon the world`s most prescribed natural human alpha interferon.

First, our analysis of the current market situation in Sweden indicates this is the opportune time to boost our sales activity. We recently announced a new advertising campaign coupled with a sales strategy that we are confident will result in sales increases over the coming months. We will ensure our return on this reasonably small investment is accounted for in a very short period of time. Sweden is the only territory, at the current time, where Viragen or one of its subsidiaries is in direct control of selling Multiferon. We must take advantage of this unique opportunity now.

Second, we are conducting a critical review, or "rationalization", of all our international distribution agreements. As part of this review, we will be making determinations as to whether to continue in certain territories or whether to halt our activities. As our marketing and regulatory resources are limited, we cannot afford to maintain product registrations in territories unless the financial return justifies the expense. Our approach will be to focus our attention on higher value opportunities.

Third, we are evaluating packaging alternatives for Multiferon in order to improve our competitiveness. Our glass ampoule presentation represents a classic approach to biological product manufacturing. However, most of our competitors use pre-filled syringes, adding to end-user convenience. While any such changes will require approvals by local authorities, this is a necessary step in managing the expectations of physicians, nurses and patients as well as positioning Multiferon for future growth.

Fourth, we are currently reviewing the regulatory alternatives for our clinical assessment of Multiferon in malignant melanoma. We are in the process of additional data collection and we expect to provide updates to you later this year on this important part of our strategy.

Finally, there are discussions and negotiations currently in progress on License and Supply Agreements for Multiferon in territories where we currently do not have a market presence, and where significant opportunities exist. These include selected areas of Asia, South America, Europe and North America. We are changing our strategy on these agreements, including our selection of collaborators. We are not going to be satisfied with merely signing agreements. Performance and growth are our priority expectations.

Based upon these and other activities, I am confident that we will realize significant improvements in revenues from Multiferon.

The U.S. Market -- With respect to the U.S. market, we have stated that, upon closing our $20 million financing agreement, we intend to use a portion of the proceeds to seek a market registration for Multiferon in the U.S. While we recognize that this process will take time and money, we know there are many different regulatory pathways available to us. We will be as creative and innovative as possible in developing a U.S. strategy. Where possible, we will make use of tools available to small businesses, tools available for niche market opportunities, and potential partnerships, whereby we may share costs of the registration processes.

If approved by Congress and the President, Project BioShield could provide a new alternative for accelerated registration, provided our products demonstrate utility in treating biological, chemical or radiation contamination. Multiferon has been demonstrated to have significant anti- viral activity in SARS in cell-based assays, and we may expect this to be active against a variety of viruses that could be used in bio-terrorism. We have been working on an international level to generate the necessary scientific data in support of Multiferon just for these purposes, and this work will continue. The critical parameter here is not just to talk about it, but to find a way to do it, and we will.

Avian Transgenic Biomanufacturing Technology
The most obvious question is, "When will the flocks of our genetically- engineered chickens be capable of producing therapeutic proteins faster, cheaper and more efficiently than conventional methods?" There is no simple answer. This is a major research project that aims to revolutionize a drug manufacturing process. The market opportunity appears to be enormous and the competition fierce. So, while we, with our partners, strive to meet internal deadlines, it is important to realize that this is discovery research. It is difficult to predict and it is not guaranteed. We are extremely encouraged by our accomplishments to date, and we believe these are but a precursor of achievements to come. We have some of the most outstanding people, partners and patents in this field, and our team is working hard to prove commercial viability. We are determined to provide our research team with the resources necessary to deliver this important technology.


Anti-Cancer Projects

We have three promising anti-cancer candidates that are being developed in collaboration with four separate and prestigious institutions, each recognized leaders in fields of cancer and immunology research. The recent grant from the Scottish Executive confirms both the credibility and innovative nature of our anti-CD55 Antibody and provides incremental funding ($833,000 over 3 years) so that we can move forward with development. Whenever possible, we will continue to utilize creative financing efforts for all of our projects. The industry is quite crowded with product candidates for the treatment of cancers. It is important that we develop sound scientific data on our candidates on as timely a basis as practical so that we can either move forward with development or stop spending money on them if they do not work. In order to realize value from these projects, we have to invest in them.

Financing
We are currently seeking stockholder approval to complete a $20 million financing agreement and to effect a 1-for-10 reverse stock split. Our Board believes these actions are necessary to enable the Company to meet its goals and build stockholder value. The intent is to recapitalize the Company in order to make our capital structure more attractive to institutional investors and professional fund managers. Adding these types of investors to our stockholder mix can help to reduce the volatility that we experience now. Coupled with improving business conditions, such as increasing sales, we expect this new financing to provide sufficient funding to allow us to move forward on our projects and ultimately build value. I believe the financing and reverse split are necessary to adequately fund our operations and to advance our development projects and I fully support these actions.

The Future
I am focused on building the business. To my knowledge, there are no sales or marketing initiatives that can be guaranteed to generate immediate revenues, short of introducing a completely new product. It will take a number of months for us to realize significant increases in sales revenues, but I am confident it will happen.

In the past two months, I have had the opportunity to meet only a few of our stockholders. Some of you have been holding shares for many years and some of you are new investors, but all of you are keenly interested in seeing your investment grow. In the coming months, I hope to be able to announce a number of events that could represent major advancements in our business.

As part of our communications, I intend to ensure that we maintain an active investor information program to report to you, the stockholder, our progress -- good or bad -- factually, accurately and as timely as possible, within the laws that govern our business.

Approaching my first 60 days as the President and CEO of Viragen, I am excited about the prospects for our Company. I also believe that tangible business accomplishments will speak louder than any predictions, and that is what you can expect from Viragen management.

Sincerely yours,


Charles A. Rice
President & CEO

Fraktal
Viragen to Present at New York Biotech Forum

PLANTATION, Fla., June 2 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Company is scheduled to present at the Informed Investors Biotechnology and Pharmaceutical Stocks Forum at the Princeton Club in New York City on June 23. The analyst-style forum, which is to include a presentation from Viragen`s President and CEO, Charles A. Rice, will be webcast following the close of the live event.

"I am looking forward to presenting Viragen`s strategy to institutional investors, not only at this conference, but also in individual meetings which have been arranged in New York and London this month," stated Mr. Rice. "With a new financing and recapitalization strategy hopefully completed by mid-June, these meetings will be important steps for communicating the investment and growth opportunities that I believe Viragen represents."

Event: Informed Investors Biotechnology and Pharmaceutical Stocks Forum
When: 8:30 a.m. (EDT)
Where: The Princeton Club, 15 West 43rd St. (Between 5th and 6th Avenues)
Fee to attend: $30 (There is no charge for webcast replay)
Keynote Speakers: Lynn Sutherland, President of Sutherland Consulting &
Bill Alpert, Senior Editor and Biotechnology Writer for
Barron`s
To register, please visit:
http://www.informedinvestors.com/CustomEvent/85117/index.asp…

About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies and a peptide drug. Viragen`s strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins.

Fraktal
Nachdem der Viragen Kurs jetzt seit einiger Zeit konstant zwischen 0,14 und 0,15 US$ gependelt hat, sehen wir heute einen Anstieg auf 0,16 US$ (entspricht 0,13 €). Das sieht auch vom Chart her interessant aus, da der Abwärtstrend seit Anfang Februar gebrochen wäre, wenn der Kurs hält !



Fraktal
Guten Morgen:)
After Hour Market auf Nasdaq com Kurse zwischen 0,18-0,19 was wird heute kommen:lick:
@ all,


was war denn gestern los bei VRA.....ein Plus von 769 %!!!

Habe ich einen RE-Split übersehen?Danke für Eure Hilfe



Thx
Ich kann die Zahlen da nicht reinstellen, weil sie sich verschieben. Also der Link:


Nach dem Split zuerst ein Abfall, aber in den letzten 2 tagen ein guter Aufwärtstrend. Ich hoffe, wir sehen bald die 2 $.

Tschonko
Kann nicht mal jemand aus Erfahrung sagen, wann die VRA´s nach´m SPLIT / RE-SPLIT oder was auch immer da passiert ist und warum wohl in Deutschland wieder handelbar werden?
Es gab einen RE-Split 10:1.
Sind die Aktien in D nicht mehr handelbar? meines Wissens gibt es nur kaum Umsätze.
Tschonko

Unter diesem Link findest du die aktuellen Nachrichten:
http://finance.yahoo.com/q?s=VRA&d=t


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um eine ältere Diskussion, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier eine neue Diskussion.